<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LATUDA- lurasidone hydrochlorideÂ tablet, film coatedÂ </strong><br>Bushu Pharmaceutical, LTD.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use LATUDA safely and effectively.  See full prescribing information for LATUDA.<br>LATUDA (LURASIDONE HCL) tablets for oral administration, <br>Initial U.S. Approval:  2010
</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span>-RELATED <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOSIS</span></span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<p class="Highlighta"><span class="Bold">Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. LATUDA is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. </span><span class="Bold"><span class="Italics">(<a href="#LINK_f0eaab5a-ee6c-4115-8951-37cea2c2763b">5.1</a>)</span></span> </p>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span>-RELATED <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOSIS</span></span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<p class="Highlighta"><span class="Bold">Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. LATUDA is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. </span><span class="Bold"><span class="Italics">(<a href="#LINK_f0eaab5a-ee6c-4115-8951-37cea2c2763b">5.1</a>)</span></span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">LATUDA is an atypical antipsychotic agent indicated for the treatment of patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> (<span class="Italics"><a href="#LINK_ed38926b-7604-43f9-9b45-4be2c89bb747">1</a></span>).  Efficacy was established in four 6-week controlled studies of adult patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> (<span class="Italics"><a href="#LINK_b76555a7-d36d-422d-8679-991a630ca45f">14.1</a></span>).
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">The recommended starting dose of LATUDA is 40 mg once daily.  Initial dose titration is not required.  The maximum recommended dose is 80 mg once daily.  LATUDA should be taken with food (<span class="Italics"><a href="#LINK_c5001172-25d4-4d1e-9c30-05cb3b59d031">2.2</a></span>).
 </p></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: 40 mg and 80 mg (<span class="Italics"><a href="#LINK_749166f5-a862-47a0-ae89-2d68971f192a">3</a></span>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div>
<p class="Highlighta">Any known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to LATUDA or any components in the formulation <span class="Italics">(</span><span class="Italics"><a href="#LINK_b4712740-0b8e-437d-97a0-fe8509a0b283">4</a></span>).
 </p>
<p class="Highlighta">Coadministration with a strong CYP3A4 inhibitor (e.g., ketoconazole) and inducer (e.g.,rifampin) (<span class="Italics"><a href="#LINK_b4712740-0b8e-437d-97a0-fe8509a0b283">4</a></span><span class="Italics">)</span>.
 </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disk">
<li>
<span class="Bold">Cerebrovascular Adverse Reactions:</span> An increased incidence of cerebrovascular adverse events (e.g., <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, transient ischemic attack) has been seen in elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related psychoses treated with atypical antipsychotic drugs. (<span class="Italics"><a href="#LINK_579b3187-ccf9-4fcd-892e-04091e630a7d">5.2</a></span>).
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span>:</span> Manage with immediate discontinuation and close monitoring (<span class="Italics"><a href="#LINK_9d59ec04-ae9a-4f61-93d2-f8eddd5387d0">5.3</a></span>).
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span>:</span> Discontinue if clinically appropriate (<span class="Italics"><a href="#LINK_aed0ff3c-2d51-4314-83f4-91c9ee97da76">5.4</a></span>).
</li>
<li>
<span class="Bold">Metabolic Changes:</span>  Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk.  These metabolic changes include <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>, and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> (<span class="Italics"><a href="#LINK_91fdf397-0baa-4105-aa32-7d65c78cb7b0">5.5</a></span>).<ul class="Circle">
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus:</span> Monitor patients for symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> including <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="438872" conceptname="Excessive eating - polyphagia">polyphagia</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>.  Monitor glucose regularly in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or at risk for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span>:</span> Undesirable alterations have been observed in patients treated with atypical antipsychotics.
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span>:</span>  Gain in body weight has been observed, clinical monitoring of weight is recommended.
</li>
</ul>
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">Hyperprolactinemia</span>:</span> Prolactin elevations may occur (<span class="Italics"><a href="#LINK_451577ea-5ce4-4f08-89b0-91372b3ded84">5.6</a></span>).
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span></span> have been reported with antipsychotics. Patients with a pre-existing low white blood cell count (WBC) or a history of <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> should have their complete blood count (CBC) monitored frequently during the first few months of therapy and LATUDA should be discontinued at the first sign of a decline in WBC in the absence of other causative factors (<span class="Italics"><a href="#LINK_122095da-5dfb-4f21-90dd-ec35a78ecf1f">5.7</a></span>).
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>:</span> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> or <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> may occur, especially early in treatment. Use with caution in patients with known cardiovascular or cerebrovascular disease, and in antipsychotic-naÃ¯ve patients (<span class="Italics"><a href="#LINK_2ce5b9e9-505b-44a7-89cc-114eb12eda61">5.8</a></span>).
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>:</span> Use cautiously in patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or with conditions that lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold (<span class="Italics"><a href="#LINK_13c948d9-935a-4a05-97c2-009bf3ebb0f0">5.9</a></span>).
</li>
<li>
<span class="Bold">Potential for Cognitive and Motor Impairment:</span> Use caution when operating machinery (<span class="Italics"><a href="#LINK_39d6b752-fbbf-434f-bb41-3329ed9c9358">5.10</a></span>).
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span>:</span> The possibility of a <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span> is inherent in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>. Closely supervise high-risk patients (<span class="Italics"><a href="#LINK_47c584b5-fa3a-483b-a1db-32ca93e53c69">5.12</a></span>).
</li>
<li> See Full Prescribing Information for additional <span class="Bold"><a href="#LINK_76e7e5ea-c51b-494d-9583-7b9e99cf4cbf">WARNINGS and PRECAUTIONS</a></span>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Commonly observed adverse reactions (incidence â‰¥5% and at least twice the rate for placebo) included <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span> and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> <span class="Italics">(</span><span class="Italics"><a href="#LINK_0bfdb801-5e52-4dcc-b22b-d60cdb88d363">6.2</a></span>).
 </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Sunovion Pharmaceuticals Inc. at   877-737-7226 or FDA at 1-800-FDA-1088 or </span><span class="Bold"><span class="Underline">www.fda.gov/medwatch</span></span>.
 </p>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disk">
<li> LATUDA is not recommended to be used in combination with strong CYP3A4 inhibitors, e.g., ketoconazole. (<span class="Italics"><a href="#LINK_b4712740-0b8e-437d-97a0-fe8509a0b283">4</a></span> and <span class="Italics"><a href="#LINK_baf95071-f5f0-4ae0-8eaf-8ae11def24b5">7.1</a></span>)
</li>
<li> Dose adjustment is recommended for moderate CYP3A4 inhibitors (e.g. diltiazem) (<span class="Italics"><a href="#LINK_baf95071-f5f0-4ae0-8eaf-8ae11def24b5">7.1</a></span>)
</li>
<li> LATUDA is not recommended to be used in combination with strong CYP3A4 inducers, e.g., rifampin. (<span class="Italics"><a href="#LINK_b4712740-0b8e-437d-97a0-fe8509a0b283">4</a></span> and <span class="Italics"><a href="#LINK_baf95071-f5f0-4ae0-8eaf-8ae11def24b5">7.1</a></span>)
</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disk">
<li>
<span class="Bold">Geriatric Use:</span> No dose adjustments required. (<span class="Italics"><a href="#LINK_288d771e-8a3b-44da-b5d1-f87bc9c26166">8.5</a></span>)
</li>
<li>
<span class="Bold">Pregnancy:</span> Use LATUDA during pregnancy only if the potential benefit justifies the potential risk. (<span class="Italics"><a href="#LINK_c20e55f7-c404-41eb-81a7-59d2a6be3975">8.1</a></span>)
</li>
<li>
<span class="Bold">Nursing Mothers:</span> Breast feeding is not recommended. (<span class="Italics"><a href="#LINK_b533c6dd-4bc7-4d8e-9412-41b568d7c5d5">8.3</a></span>)
</li>
<li>
<span class="Bold">Pediatric Use:</span> Safety and effectiveness have not been established. (<span class="Italics"><a href="#LINK_8e2056b4-5332-498b-b5e6-4b6872a16530">8.4</a></span>)
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> Dose adjustment is recommended. (<span class="Italics"><a href="#LINK_410f4f2b-4053-41f4-9510-879655a86c86">8.6</a></span>)
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span> Dose adjustment is recommended. (<span class="Italics"><a href="#LINK_2c3d9570-f11c-45dd-a9d4-89a403e39d2e">8.7</a></span>)
</li>
</ul></div>
<div>
<div><div></div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 11/2010</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span>-RELATED <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOSIS</span>
</a></h1>
<h1><a href="#section-1" class="toc">1. INDICATIONS AND USAGE
</a></h1>
<h1><a href="#section-2" class="toc">2. DOSAGE AND ADMINISTRATION
</a></h1>
<h2><a href="#section-2.1" class="toc">2.1. <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span>
</a></h2>
<h2><a href="#section-2.2" class="toc">2.2. Administration Instructions
</a></h2>
<h2><a href="#section-2.3" class="toc">2.3. Dosage in Special Populations
</a></h2>
<h1><a href="#section-3" class="toc">3. DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-4" class="toc">4. CONTRAINDICATIONS
</a></h1>
<h1><a href="#section-5" class="toc">5. WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-5.1" class="toc">5.1. Increased Mortality in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span>
</a></h2>
<h2><a href="#section-5.2" class="toc">5.2. Cerebrovascular Adverse Reactions, Including <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span>
</a></h2>
<h2><a href="#section-5.3" class="toc">5.3. <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span>
</a></h2>
<h2><a href="#section-5.4" class="toc">5.4.  <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span>
</a></h2>
<h2><a href="#section-5.5" class="toc">5.5.  Metabolic Changes
</a></h2>
<h2><a href="#section-5.6" class="toc">5.6. <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">Hyperprolactinemia</span>
</a></h2>
<h2><a href="#section-5.7" class="toc">5.7. <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>
</a></h2>
<h2><a href="#section-5.8" class="toc">5.8. <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>
</a></h2>
<h2><a href="#section-5.9" class="toc">5.9. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>
</a></h2>
<h2><a href="#section-5.10" class="toc">5.10. Potential for Cognitive and Motor Impairment
</a></h2>
<h2><a href="#section-5.11" class="toc">5.11. Body Temperature Regulation
</a></h2>
<h2><a href="#section-5.12" class="toc">5.12. <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span>
</a></h2>
<h2><a href="#section-5.13" class="toc">5.13. <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span>
</a></h2>
<h2><a href="#section-5.14" class="toc">5.14. Use in Patients with Concomitant Illness
</a></h2>
<h1><a href="#section-6" class="toc">6. ADVERSE REACTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">6.1. Overall Adverse Reaction Profile
</a></h2>
<h2><a href="#section-6.2" class="toc">6.2. Clinical Studies Experience
</a></h2>
<h2><a href="#section-6.3" class="toc">6.3. Dose-Related Adverse Reactions
</a></h2>
<h2><a href="#section-6.4" class="toc">6.4. <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal Symptoms</span>
</a></h2>
<h2><a href="#section-6.5" class="toc">6.5. Laboratory Test Abnormalities and ECG Changes in Clinical Studies
</a></h2>
<h2><a href="#section-6.6" class="toc">6.6. Other Adverse Reactions Observed During the Premarketing Evaluation of LATUDA
</a></h2>
<h1><a href="#section-7" class="toc">7. DRUG INTERACTIONS
</a></h1>
<h2><a href="#section-7.1" class="toc">7.1. Potential for Other Drugs to Affect LATUDA
</a></h2>
<h2><a href="#section-7.2" class="toc">7.2. Potential for LATUDA to Affect Other Drugs
</a></h2>
<h1><a href="#section-8" class="toc">8. USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-8.1" class="toc">8.1. Pregnancy
</a></h2>
<h2><a href="#section-8.2" class="toc">8.2. Labor and Delivery
</a></h2>
<h2><a href="#section-8.3" class="toc">8.3. Nursing Mothers
</a></h2>
<h2><a href="#section-8.4" class="toc">8.4. Pediatric Use
</a></h2>
<h2><a href="#section-8.5" class="toc">8.5. Geriatric Use
</a></h2>
<h2><a href="#section-8.6" class="toc">8.6. <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</a></h2>
<h2><a href="#section-8.7" class="toc">8.7. <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</a></h2>
<h2><a href="#section-8.8" class="toc">8.8. Gender
</a></h2>
<h2><a href="#section-8.9" class="toc">8.9. Race
</a></h2>
<h2><a href="#section-8.10" class="toc">8.10. Smoking Status
</a></h2>
<h1><a href="#section-9" class="toc">9. DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span>
</a></h1>
<h2><a href="#section-9.1" class="toc">9.1. Controlled substance
</a></h2>
<h2><a href="#section-9.2" class="toc">9.2. Abuse
</a></h2>
<h1><a href="#section-10" class="toc">10. OVERDOSAGE
</a></h1>
<h2><a href="#section-10.1" class="toc">10.1. Human Experience
</a></h2>
<h2><a href="#section-10.2" class="toc">10.2. Management of Overdosage
</a></h2>
<h1><a href="#section-11" class="toc">11. DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12. CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-12.1" class="toc">12.1. Mechanism of Action
</a></h2>
<h2><a href="#section-12.2" class="toc">12.2. Pharmacodynamics
</a></h2>
<h2><a href="#section-12.3" class="toc">12.3. Pharmacokinetics
</a></h2>
<h1><a href="#section-13" class="toc">13. NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-13.1" class="toc"></a></h2>
<h2><a href="#section-13.2" class="toc"></a></h2>
<h2><a href="#section-13.3" class="toc"></a></h2>
<h1><a href="#section-14" class="toc">14. CLINICAL STUDIES
</a></h1>
<h2><a href="#section-14.1" class="toc">14.1. <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></a></h2>
<h1><a href="#section-15" class="toc">16. HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-15.1" class="toc"></a></h2>
<h1><a href="#section-16" class="toc">17. PATIENT COUNSELING INFORMATION
</a></h1>
<h2><a href="#section-16.1" class="toc">17.1 Increased Mortality in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span>
</a></h2>
<h2><a href="#section-16.2" class="toc">17.2 <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span>
</a></h2>
<h2><a href="#section-16.3" class="toc">17.3 <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus
</a></h2>
<h2><a href="#section-16.4" class="toc">17.4 <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span>
</a></h2>
<h2><a href="#section-16.5" class="toc">17.5 <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>
</a></h2>
<h2><a href="#section-16.6" class="toc">17.6 Interference with Cognitive and Motor Performance
</a></h2>
<h2><a href="#section-16.7" class="toc">17.7 Pregnancy and Nursing
</a></h2>
<h2><a href="#section-16.8" class="toc">17.8 Concomitant Medication and Alcohol
</a></h2>
<h2><a href="#section-16.9" class="toc">17.9 Heat Exposure and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span>
</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="LINK_48c8dd45-b54e-425d-94ca-27545cd41a23"></a><a name="section-1"></a><p></p>
<h1>WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span>-RELATED <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">PSYCHOSIS</span>
</h1>
<p class="First"><span class="Bold">Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in drug-treated patients of between 1.6 to 1.7 times the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were varied, most of the <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> appeared to be either cardiovascular (e.g., <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>) or infectious (e.g., <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>) in nature.</span></p>
<p><span class="Bold">Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear.</span></p>
<p><span class="Bold">LATUDA is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>.
</span><span class="Bold"><span class="Italics">[see Warnings and Precautions (</span></span><span class="Bold"><span class="Italics"><a href="#LINK_f0eaab5a-ee6c-4115-8951-37cea2c2763b">5.1
</a></span></span><span class="Bold"><span class="Italics">)]</span></span>.
</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_ed38926b-7604-43f9-9b45-4be2c89bb747"></a><a name="section-1"></a><p></p>
<h1>1. INDICATIONS AND USAGE
</h1>
<p class="First">LATUDA is indicated for the treatment of patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>.
</p>
<p>The efficacy of LATUDA in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> was established in four 6-week controlled studies of adult patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> <span class="Italics">[see Clinical Studies (</span><span class="Italics"><a href="#LINK_b76555a7-d36d-422d-8679-991a630ca45f">14.1</a></span><span class="Italics">)].</span></p>
<p>The effectiveness of LATUDA for longer-term use, that is, for more than 6 weeks, has not been established in controlled studies.  Therefore, the physician who elects to use LATUDA for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient <span class="Italics">[see Dosage and Administration (</span><span class="Italics"><a href="#LINK_a097aafe-6919-4401-9bc5-fddec7e18d5e">2</a></span><span class="Italics">)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_a097aafe-6919-4401-9bc5-fddec7e18d5e"></a><a name="section-2"></a><p></p>
<h1>2. DOSAGE AND ADMINISTRATION
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_90076bdd-ac06-401f-8f0b-129a828d2c33"></a><a name="section-2.1"></a><p></p>
<h2>2.1. <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span>
</h2>
<p class="First">The recommended starting dose of LATUDA is 40 mg once daily.  Initial dose titration is not required. LATUDA has been shown to be effective in a dose range of 40 mg/day to 120 mg/day [<span class="Italics">see Clinical Studies (</span><span class="Italics"><a href="#LINK_b76555a7-d36d-422d-8679-991a630ca45f">14.1</a></span><span class="Italics">)</span>]. In the 6-week controlled trials, there was no suggestion of added benefit with the 120 mg/day dose, but there was a dose-related increase in certain adverse reactions. Therefore, the maximum recommended dose is 80 mg/day. 
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c5001172-25d4-4d1e-9c30-05cb3b59d031"></a><a name="section-2.2"></a><p></p>
<h2>2.2. Administration Instructions
</h2>
<p class="First">LATUDA should be taken with food (at least 350 calories) [<span class="Italics">see Clinical Pharmacology (</span><span class="Italics"><a href="#LINK_1312e395-defc-4f97-8c14-ccbbfef1ac79">12</a></span><span class="Italics">)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d69a7bb8-3c47-4720-b0cc-34ca02c30ba1"></a><a name="section-2.3"></a><p></p>
<h2>2.3. Dosage in Special Populations
</h2>
<p class="First">Dosage adjustments are not recommended on the basis of age, gender, and race <span class="Italics">[see Use in Specific Populations (</span><span class="Italics"><a href="#LINK_437f91ce-1c25-42a6-98c6-508ae49fdc24">8</a></span><span class="Italics">)].</span></p>
<p>Dose adjustment is recommended in moderate and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> patients.  The dose in these patients should not exceed 40 mg/day <span class="Italics">[see Use in Specific Populations (</span><span class="Italics"><a href="#LINK_437f91ce-1c25-42a6-98c6-508ae49fdc24">8</a></span><span class="Italics">)].</span></p>
<p>Dose adjustment is recommended in moderate and severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> patients.  The dose in these patients should not exceed 40 mg/day <span class="Italics">[see Use in Specific Populations (</span><span class="Italics"><a href="#LINK_437f91ce-1c25-42a6-98c6-508ae49fdc24">8</a></span><span class="Italics">)].</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_4cc2980c-6c51-488d-88e9-c8d62dabf138"></a><a name="section-2.3.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold">Dosing recommendation for patients taking LATUDA concomitantly with potential CYP3A4 inhibitors:</span> When coadministration of LATUDA with a moderate CYP3A4 inhibitor such as diltiazem is considered, the dose should not exceed 40 mg/day.  LATUDA should not be used in combination with a strong CYP3A4 inhibitor (e.g., ketoconazole) <span class="Italics">[see Contraindications (</span><span class="Italics"><a href="#LINK_b4712740-0b8e-437d-97a0-fe8509a0b283">4</a></span><span class="Italics">); Drug Interactions (</span><span class="Italics"><a href="#LINK_baf95071-f5f0-4ae0-8eaf-8ae11def24b5">7.1</a></span><span class="Italics">)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3ce1a4fb-8625-4f18-8fca-69a9310f6d54"></a><a name="section-2.3.2"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold">Dosing recommendation for patients taking LATUDA concomitantly with potential CYP3A4 inducers:</span> LATUDA should not be used in combination with a strong CYP3A4 inducer (e.g., rifampin) <span class="Italics">[see Contraindications (</span><span class="Italics"><a href="#LINK_b4712740-0b8e-437d-97a0-fe8509a0b283">4</a></span><span class="Italics">); Drug Interactions (</span><span class="Italics"><a href="#LINK_baf95071-f5f0-4ae0-8eaf-8ae11def24b5">7.1</a></span><span class="Italics">)]</span>.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="LINK_749166f5-a862-47a0-ae89-2d68971f192a"></a><a name="section-3"></a><p></p>
<h1>3. DOSAGE FORMS AND STRENGTHS
</h1>
<p class="First">LATUDA tablets are available in the following shape and color (TableÂ 1) with respective one-sided debossing: 40 mg (white to off-white, round, â€œL40â€?), or 80 mg (<span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> green, oval, â€œL80â€?).
</p>
<table>
<caption><span>TableÂ 1: LATUDA Tablet Presentations
</span></caption>
<col>
<col>
<col>
<thead><tr class="First Last">
<th class="Botrule Toprule" align="center" valign="top"><span class="Bold">Tablet Strength</span></th>
<th class="Botrule Toprule" align="center" valign="top"><span class="Bold">Tablet Color/Shape</span></th>
<th class="Botrule Toprule" align="center" valign="top"><span class="Bold">Tablet Markings</span></th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule" align="center" valign="top">Â 40 mg
</td>
<td class="Botrule" align="center" valign="top">Â white to off-white round
</td>
<td class="Botrule" align="center" valign="top">Â â€œL40â€?
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="top">Â 80 mg
</td>
<td class="Botrule" align="center" valign="top">Â <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> green oval
</td>
<td class="Botrule" align="center" valign="top">Â â€œL80â€?
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_b4712740-0b8e-437d-97a0-fe8509a0b283"></a><a name="section-4"></a><p></p>
<h1>4. CONTRAINDICATIONS
</h1>
<p class="First">LATUDA is contraindicated in any patient with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to lurasidone HCl or any components in the formulation.  <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> has been observed with lurasidone [<span class="Italics">see Adverse Reactions (</span><span class="Italics"><a href="#LINK_1c4b542d-ed65-46b8-a7e1-3aa57075247c">6.6</a></span><span class="Italics">)</span>]. 
</p>
<p>LATUDA is contraindicated with strong CYP3A4 inhibitors (e.g., ketoconazole) and strong CYP3A4 inducers (e.g., rifampin) [<span class="Italics">see Drug Interactions (<a href="#LINK_baf95071-f5f0-4ae0-8eaf-8ae11def24b5">7.1</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_76e7e5ea-c51b-494d-9583-7b9e99cf4cbf"></a><a name="section-5"></a><p></p>
<h1>5. WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f0eaab5a-ee6c-4115-8951-37cea2c2763b"></a><a name="section-5.1"></a><p></p>
<h2>5.1. Increased Mortality in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span>
</h2>
<p class="First"><span class="Bold">Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. LATUDA is not approved for the treatment of <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> [<span class="Italics">see <a href="#LINK_48c8dd45-b54e-425d-94ca-27545cd41a23">Boxed Warning</a></span>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_579b3187-ccf9-4fcd-892e-04091e630a7d"></a><a name="section-5.2"></a><p></p>
<h2>5.2. Cerebrovascular Adverse Reactions, Including <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span>
</h2>
<p class="First">In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>, there was a higher incidence of cerebrovascular adverse reactions (<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accidents</span> and <span class="product-label-link" type="condition" conceptid="373503" conceptname="Transient cerebral ischemia">transient ischemic attacks</span>), including fatalities, compared to placebo-treated subjects.  LATUDA is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> <span class="Italics">[see also <a href="#LINK_48c8dd45-b54e-425d-94ca-27545cd41a23">Boxed Warning</a> and Warnings and Precautions (</span><span class="Italics"><a href="#LINK_f0eaab5a-ee6c-4115-8951-37cea2c2763b">5.1</a></span><span class="Italics">)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9d59ec04-ae9a-4f61-93d2-f8eddd5387d0"></a><a name="section-5.3"></a><p></p>
<h2>5.3. <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span>
</h2>
<p class="First">A potentially fatal symptom complex sometimes referred to as <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS) has been reported in association with administration of antipsychotic drugs, including LATUDA.
</p>
<p>Clinical manifestations of NMS are <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, altered mental status, and evidence of <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (<span class="product-label-link" type="condition" conceptid="4088122" conceptname="Heart irregular">irregular pulse</span> or blood pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, and cardiac dysrhythmia). Additional signs may include elevated creatinine phosphokinase, <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span> (<span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>), and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>.
</p>
<p>The diagnostic evaluation of patients with this syndrome is complicated. It is important to exclude cases where the clinical presentation includes both serious medical illness (e.g. <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS).  Other important considerations in the differential diagnosis include central anticholinergic toxicity, <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span>, and primary central nervous system pathology.
</p>
<p>The management of NMS should include: 1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; 2) intensive symptomatic treatment and medical monitoring; and 3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for NMS.
</p>
<p>If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered.  If reintroduced, the patient should be carefully monitored, since recurrences of NMS have been reported.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_aed0ff3c-2d51-4314-83f4-91c9ee97da76"></a><a name="section-5.4"></a><p></p>
<h2>5.4.  <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span> is a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements that can develop in patients treated with antipsychotic drugs.  Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome.  Whether antipsychotic drug products differ in their potential to cause <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> is unknown.
</p>
<p>The risk of developing <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase.  However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses.
</p>
<p>There is no known treatment for established cases of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn.  Antipsychotic treatment, itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying process.  The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown.
</p>
<p>Given these considerations, LATUDA should be prescribed in a manner that is most likely to minimize the occurrence of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>.  Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that (1) is known to respond to antipsychotic drugs, and (2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate.  In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought.  The need for continued treatment should be reassessed periodically.
</p>
<p>If signs and symptoms of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> appear in a patient on LATUDA, drug discontinuation should be considered.  However, some patients may require treatment with LATUDA despite the presence of the syndrome.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_91fdf397-0baa-4105-aa32-7d65c78cb7b0"></a><a name="section-5.5"></a><p></p>
<h2>5.5.  Metabolic Changes
</h2>
<p class="First">Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk.  These metabolic changes include <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>, and body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>.  While all of the drugs in the class have been shown to produce some metabolic changes, each drug has its own specific risk profile.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_cd6f7691-455c-473c-9941-126cd22c3201"></a><a name="section-5.5.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus</span></p>
<p><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>, in some cases extreme and associated with <span class="product-label-link" type="condition" conceptid="4209145" conceptname="Ketoacidosis">ketoacidosis</span> or hyperosmolar <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, has been reported in patients treated with atypical antipsychotics.  Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus in patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and the increasing incidence of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus in the general population.  Given these confounders, the relationship between atypical antipsychotic use and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>-related adverse events is not completely understood.  However, epidemiological studies suggest an increased risk of treatment-emergent <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>-related adverse events in patients treated with the atypical antipsychotics.  Because LATUDA was not marketed at the time these studies were performed, it is not known if LATUDA is associated with this increased risk. 
</p>
<p>Patients with an established diagnosis of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control.  Patients with risk factors for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus (e.g., <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, family history of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment.  Any patient treated with atypical antipsychotics should be monitored for symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> including <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="438872" conceptname="Excessive eating - polyphagia">polyphagia</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>.  Patients who develop symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.  
</p>
<p>Pooled data from short-term, placebo-controlled studies are presented in TableÂ 2.
</p>
<table>
<caption><span>TableÂ 2: Change in Fasting Glucose
</span></caption>
<col>
<col>
<col>
<col>
<col>
<col>
<thead>
<tr class="First">
<th class="Botrule Toprule" align="center" valign="top"></th>
<th class="Botrule Toprule" align="center" valign="top">
<br><span class="Bold">Placebo</span>
</th>
<th class="Botrule Toprule" align="center" valign="top">
<span class="Bold">LATUDA</span><br><span class="Bold">20 mg/day</span>
</th>
<th class="Botrule Toprule" align="center" valign="top">
<span class="Bold">LATUDA</span><br><span class="Bold">40 mg/day</span>
</th>
<th class="Botrule Toprule" align="center" valign="top">
<span class="Bold">LATUDA</span><br><span class="Bold">80 mg/day</span>
</th>
<th class="Botrule Toprule" align="center" valign="top">
<span class="Bold">LATUDA</span><br><span class="Bold">120 mg/day</span>
</th>
</tr>
<tr><th class="Botrule" align="center" colspan="6" valign="top"><span class="Bold">Mean Change from Baseline (mg/dL)</span></th></tr>
<tr class="Last">
<th class="Botrule" align="center" valign="top"></th>
<th class="Botrule" align="center" valign="top"><span class="Bold">n=438</span></th>
<th class="Botrule" align="center" valign="top"><span class="Bold">n=71</span></th>
<th class="Botrule" align="center" valign="top"><span class="Bold">n=352</span></th>
<th class="Botrule" align="center" valign="top"><span class="Bold">n=270</span></th>
<th class="Botrule" align="center" valign="top"><span class="Bold">n=283</span></th>
</tr>
</thead>
<tfoot><tr class="First Last"><td colspan="6" valign="top">Â <p class="First">In the uncontrolled, longer-term studies (primarily open-label extension studies), LATUDA was associated with a mean change in glucose of +1.6 mg/dL at week 24 (n = 186), +0.3 mg/dL at week 36 (n = 236) and +1.2 mg/dL at week 52 (n = 244).
</p>
</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule" valign="top">Â Serum Glucose
</td>
<td class="Botrule" align="center" valign="top">Â -0.7
</td>
<td class="Botrule" align="center" valign="top">Â -0.6
</td>
<td class="Botrule" align="center" valign="top">Â 2.5
</td>
<td class="Botrule" align="center" valign="top">Â -0.9
</td>
<td class="Botrule" align="center" valign="top">Â 2.5
</td>
</tr>
<tr><td class="Botrule" align="center" colspan="6" valign="top">Â <span class="Bold">Proportion of Patients with Shifts to â‰¥ 126 mg/dL</span>
</td></tr>
<tr class="Last">
<td class="Botrule" valign="top">Â Serum Glucose <br>(â‰¥ 126 mg/dL)
</td>
<td class="Botrule" align="center" valign="top">Â 8.6%<br>(34/397)
</td>
<td class="Botrule" align="center" valign="top">Â 11.7%<br>(7/60)
</td>
<td class="Botrule" align="center" valign="top">Â 14.3%<br>( 47/328)
</td>
<td class="Botrule" align="center" valign="top">Â 10.0%<br>(24/241)
</td>
<td class="Botrule" align="center" valign="top">Â 10.0%<br>(26/260)
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_553c0927-3216-456b-9705-b95b476e151f"></a><a name="section-5.5.2"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span></span></p>
<p>Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics. Pooled data from short-term, placebo-controlled studies are presented in Table 3.
</p>
<table>
<caption><span>TableÂ 3: Change in Fasting Lipids
</span></caption>
<col>
<col>
<col>
<col>
<col>
<col>
<thead>
<tr class="First">
<th class="Botrule Toprule" align="center" valign="top"></th>
<th class="Botrule Toprule" align="center" valign="top">
<br><span class="Bold">Placebo</span>
</th>
<th class="Botrule Toprule" align="center" valign="top">
<span class="Bold">LATUDA</span><br><span class="Bold">20 mg/day</span>
</th>
<th class="Botrule Toprule" align="center" valign="top">
<span class="Bold">LATUDA</span><br><span class="Bold">40 mg/day</span>
</th>
<th class="Botrule Toprule" align="center" valign="top">
<span class="Bold">LATUDA</span><br><span class="Bold">80 mg/day</span>
</th>
<th class="Botrule Toprule" align="center" valign="top">
<span class="Bold">LATUDA</span><br><span class="Bold">120 mg/day</span>
</th>
</tr>
<tr><th class="Botrule" align="center" colspan="6" valign="top"><span class="Bold">Mean Change from Baseline (mg/dL)</span></th></tr>
<tr class="Last">
<th class="Botrule" align="center" valign="top"></th>
<th class="Botrule" align="center" valign="top"><span class="Bold">n=418</span></th>
<th class="Botrule" align="center" valign="top"><span class="Bold">n=71</span></th>
<th class="Botrule" align="center" valign="top"><span class="Bold">n=341</span></th>
<th class="Botrule" align="center" valign="top"><span class="Bold">n=263</span></th>
<th class="Botrule" align="center" valign="top"><span class="Bold">n=268</span></th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule" valign="top">Â Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>
</td>
<td class="Botrule" align="center" valign="top">Â -8.5
</td>
<td class="Botrule" align="center" valign="top">Â -12.3
</td>
<td class="Botrule" align="center" valign="top">Â -9.4
</td>
<td class="Botrule" align="center" valign="top">Â -9.8
</td>
<td class="Botrule" align="center" valign="top">Â -3.8
</td>
</tr>
<tr>
<td class="Botrule" valign="top">Â Triglycerides
</td>
<td class="Botrule" align="center" valign="top">Â -15.7
</td>
<td class="Botrule" align="center" valign="top">Â -29.1
</td>
<td class="Botrule" align="center" valign="top">Â -6.2
</td>
<td class="Botrule" align="center" valign="top">Â -14.2
</td>
<td class="Botrule" align="center" valign="top">Â -3.1
</td>
</tr>
<tr><td class="Botrule" align="center" colspan="6" valign="top">Â <span class="Bold">Proportion of Patients with Shifts</span>
</td></tr>
<tr>
<td class="Botrule" valign="top">Â Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> <br>(â‰¥ 240 mg/dL)
</td>
<td class="Botrule" align="center" valign="top">Â 6.6%<br>(23/350)
</td>
<td class="Botrule" align="center" valign="top">Â 13.8%<br>(8/58)
</td>
<td class="Botrule" align="center" valign="top">Â 7.3%<br>(21/287)
</td>
<td class="Botrule" align="center" valign="top">Â 6.9%<br>(15/216)
</td>
<td class="Botrule" align="center" valign="top">Â 3.8%<br>(9/238)
</td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top">Â Triglycerides <br>(â‰¥ 200 mg/dL)
</td>
<td class="Botrule" align="center" valign="top">Â 12.5%<br>(39/312)
</td>
<td class="Botrule" align="center" valign="top">Â 14.3%<br>(7/49)
</td>
<td class="Botrule" align="center" valign="top">Â 14.0%<br>(37/264)
</td>
<td class="Botrule" align="center" valign="top">Â 8.7%<br>(17/196)
</td>
<td class="Botrule" align="center" valign="top">Â 10.5%<br>(22/209)
</td>
</tr>
</tbody>
</table>
<p>In the uncontrolled, longer-term studies (primarily open-label extension studies), LATUDA was associated with a mean change in total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglycerides of -4.2 (n=186) and -13.6 (n=187) mg/dL at week 24, -1.9 (n = 238) and -3.5 (n = 238) mg/dL at week 36 and -3.6 (n=243) and -6.5 (n=243) mg/dL at week 52, respectively.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_937aa973-7f20-408d-819d-b3f2cad2047f"></a><a name="section-5.5.3"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span> has been observed with atypical antipsychotic use.  Clinical monitoring of weight is recommended.
</p>
<p>Pooled data from short-term, placebo-controlled studies are presented in Table 4.  The mean <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> was 0.75 kg for LATUDA-treated patients compared to 0.26 kg for placebo-treated patients. In study 3 [<span class="Italics">see Clinical Studies (<a href="#LINK_b76555a7-d36d-422d-8679-991a630ca45f">14.1</a>)</span>] change in weight from baseline for olanzapine was 4.15 kg.  The proportion of patients with a â‰¥ 7% increase in body weight (at Endpoint) was 5.6% for LATUDA-treated patients versus 4.0% for placebo-treated patients. 
</p>
<table>
<caption><span>TableÂ 4: Mean Change in Weight (kg) from Baseline
</span></caption>
<col width="14.633%">
<col width="14.100%">
<col width="18.717%">
<col width="18.717%">
<col width="18.100%">
<col width="15.733%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="center" valign="top">Â </td>
<td class="Botrule Toprule" align="center" valign="top">Â <br><span class="Bold">Placebo</span><br><span class="Bold">(n=450)</span>
</td>
<td class="Botrule Toprule" align="center" valign="top">Â <span class="Bold">LATUDA<br>20 mg/day</span><br><span class="Bold">(n=71)</span>
</td>
<td class="Botrule Toprule" align="center" valign="top">Â <span class="Bold">LATUDA <br>40 mg/day</span><br><span class="Bold">(n= 358)</span>
</td>
<td class="Botrule Toprule" align="center" valign="top">Â <span class="Bold">LATUDA<br>80 mg/day</span><br><span class="Bold">(n= 279)</span>
</td>
<td class="Botrule Toprule" align="center" valign="top">Â <span class="Bold">LATUDA <br>120 mg/day</span><br><span class="Bold">(n=291)</span>
</td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top">Â All Patients
</td>
<td class="Botrule" align="center" valign="top">Â 0.26
</td>
<td class="Botrule" align="center" valign="top">Â -0.15
</td>
<td class="Botrule" align="center" valign="top">Â 0.67
</td>
<td class="Botrule" align="center" valign="top">Â 1.14
</td>
<td class="Botrule" align="center" valign="top">Â 0.68
</td>
</tr>
</tbody>
</table>
<p>In the uncontrolled, longer-term studies (primarily open-label extension studies), LATUDA was associated with a mean change in weight of -0.38 kg at week 24 (n = 531), -0.47 kg at week 36 (n = 303) and -0.71 kg at week 52 (n = 244). 
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_451577ea-5ce4-4f08-89b0-91372b3ded84"></a><a name="section-5.6"></a><p></p>
<h2>5.6. <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">Hyperprolactinemia</span>
</h2>
<p class="First">As with other drugs that antagonize dopamine D<span class="Sub">2</span> receptors, LATUDA elevates prolactin levels.  
</p>
<p><span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">Hyperprolactinemia</span> may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotrophin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.  <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">Galactorrhea</span>, <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, and <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span> have been reported with prolactin-elevating compounds.  Long-standing <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">hyperprolactinemia</span> when associated with <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span> may lead to decreased bone density in both female and male patients <span class="Italics">[see Adverse Reactions (</span><span class="Italics"><a href="#LINK_7c7518b1-dcb4-4dd3-96dc-a8cf5d1c285a">6</a></span><span class="Italics">)]</span>.
</p>
<p>In short-term placebo-controlled studies, the median change from baseline to endpoint in prolactin levels for LATUDA-treated patients was 1.1 ng/mL and was - 0.6 ng/mL in the placebo-treated patients.  The increase in prolactin was greater in female patients; the median change from baseline to endpoint for females was 1.5 ng/mL and was 1.1 ng/mL in males.  The increase in prolactin concentrations was dose-dependent (Table 5).
</p>
<table>
<caption><span>TableÂ 5: Median Change in Prolactin (ng/mL) from Baseline
</span></caption>
<col width="14.633%">
<col width="14.100%">
<col width="18.717%">
<col width="18.717%">
<col width="18.100%">
<col width="15.733%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="center" valign="top">Â </td>
<td class="Botrule Toprule" align="center" valign="top">Â <span class="Bold">Placebo</span>
</td>
<td class="Botrule Toprule" align="center" valign="top">Â <span class="Bold">LATUDA<br>20 mg/day</span>
</td>
<td class="Botrule Toprule" align="center" valign="top">Â <span class="Bold">LATUDA <br>40 mg/day</span>
</td>
<td class="Botrule Toprule" align="center" valign="top">Â <span class="Bold">LATUDA<br>80 mg/day</span>
</td>
<td class="Botrule Toprule" align="center" valign="top">Â <span class="Bold">LATUDA <br>120 mg/day</span>
</td>
</tr>
<tr>
<td class="Botrule" valign="top">Â All Patients
</td>
<td class="Botrule" align="center" valign="top">Â -0.6<br>(n=430)
</td>
<td class="Botrule" align="center" valign="top">Â -1.1<br>(n=70)
</td>
<td class="Botrule" align="center" valign="top">Â 0.3<br>(n=351)
</td>
<td class="Botrule" align="center" valign="top">Â 1.1<br>(n=259)
</td>
<td class="Botrule" align="center" valign="top">Â 3.3<br>(n=284)
</td>
</tr>
<tr>
<td class="Botrule" valign="top">Â Females
</td>
<td class="Botrule" align="center" valign="top">Â -1.5<br>(n=102)
</td>
<td class="Botrule" align="center" valign="top">Â -0.7<br>(n=19)
</td>
<td class="Botrule" align="center" valign="top">Â -0.9<br>(n=99)
</td>
<td class="Botrule" align="center" valign="top">Â 2.0<br>(n=78)
</td>
<td class="Botrule" align="center" valign="top">Â 6.7<br>(n=70)
</td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top">Â Males
</td>
<td class="Botrule" align="center" valign="top">Â -0.5<br>(n=328)
</td>
<td class="Botrule" align="center" valign="top">Â -1.2<br>(n=51)
</td>
<td class="Botrule" align="center" valign="top">Â 0.5<br>(n=252)
</td>
<td class="Botrule" align="center" valign="top">Â 0.9<br>(n=181)
</td>
<td class="Botrule" align="center" valign="top">Â 3.1<br>(n=214)
</td>
</tr>
</tbody>
</table>
<p>The proportion of patients with prolactin elevations â‰¥ 5Ã— ULN was 3.6% for LATUDA-treated patients versus 0.7% for placebo-treated patients.  The proportion of female patients with prolactin elevations
â‰¥ 5x ULN was 8.3% for LATUDA-treated patients versus 1% for placebo-treated female patients.  The proportion of male patients with prolactin elevations &gt; 5x ULN was 1.9% versus 0.6% for placebo-treated male patients.
</p>
<p>In the uncontrolled longer-term studies (primarily open-label extension studies), LATUDA was associated with a median change in prolactin of -1.9 ng/mL at week 24 (n = 188), -5.4 ng/mL at week 36 (n=189) and       -3.3 ng/mL at week 52 (n = 243).
</p>
<p>Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin dependent in vitro, a factor of potential importance if the prescription of these drugs is considered in a patient with previously detected breast cancer.  As is common with compounds which increase prolactin release, an increase in mammary gland neoplasia was observed in a LATUDA carcinogenicity study conducted in rats and mice <span class="Italics">[see Nonclinical Toxicology (</span><span class="Italics"><a href="#LINK_bc15f8e6-29f3-427e-b13b-e6d60a68ef21">13</a></span><span class="Italics">)].</span>  Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans, but the available evidence is too limited to be conclusive.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_122095da-5dfb-4f21-90dd-ec35a78ecf1f"></a><a name="section-5.7"></a><p></p>
<h2>5.7. <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> has been reported during treatment with antipsychotic agents.  <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span> (including fatal cases) has been reported with other agents in the class.
</p>
<p>Possible risk factors for <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> include pre-existing low white blood cell count (WBC) and history of drug induced <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>.  Patients with a pre-existing low WBC or a history of drug induced <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> should have their complete blood count (CBC) monitored frequently during the first few months of therapy and LATUDA should be discontinued at the first sign of decline in WBC, in the absence of other causative factors.
</p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> should be carefully monitored for <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or other symptoms or signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and treated promptly if such symptoms or signs occur.  Patients with severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (absolute neutrophil count &lt; 1000/mm<span class="Sup">3</span>) should discontinue LATUDA and have their WBC followed until recovery. 
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2ce5b9e9-505b-44a7-89cc-114eb12eda61"></a><a name="section-5.8"></a><p></p>
<h2>5.8. <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>
</h2>
<p class="First">LATUDA may cause <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, perhaps due to its Î±1-adrenergic receptor antagonism.  The incidence of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> events from short-term, placebo-controlled studies was (LATUDA incidence, placebo incidence): <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> [0.4% (4/1004), 0.2 % (1/455)] and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> [&lt; 0.1% (1/1004), 0%].  Assessment of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> defined by vital sign changes (â‰¥ 20 mm Hg decrease in systolic blood pressure and
â‰¥ 10 bpm increase in pulse from sitting to standing or supine to standing positions).  In short-term clinical trials <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> occurred with a frequency of 0.8% with LATUDA 40 mg, 1.4% with LATUDA 80 mg and 1.7% with LATUDA 120 mg compared to 0.9% with placebo.
</p>
<p>LATUDA should be used with caution in patients with known cardiovascular disease (e.g., <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, or conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (e.g., <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>, and treatment with antihypertensive medications).  Monitoring of orthostatic vital signs should be considered in patients who are vulnerable to <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. 
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_13c948d9-935a-4a05-97c2-009bf3ebb0f0"></a><a name="section-5.9"></a><p></p>
<h2>5.9. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>
</h2>
<p class="First">As with other antipsychotic drugs, LATUDA should be used cautiously in patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or with conditions that lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold, e.g., Alzheimer's <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>.  Conditions that lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold may be more prevalent in patients 65 years or older.
</p>
<p>In short-term placebo-controlled trials, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>/<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> occurred in &lt; 0.1% (1/1004) of patients treated with LATUDA compared to 0.2% (1/455) placebo-treated patients.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_39d6b752-fbbf-434f-bb41-3329ed9c9358"></a><a name="section-5.10"></a><p></p>
<h2>5.10. Potential for Cognitive and Motor Impairment
</h2>
<p class="First">LATUDA, like other antipsychotics, has the potential to impair judgment, thinking or motor skills. 
</p>
<p>In short-term, placebo-controlled trials, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> was reported in 22.3% (224/1004) of patients treated with LATUDA compared to 9.9% (45/455) of placebo patients, respectively.  The frequency of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> increases with dose; <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> was reported in 26.5% (77/291) of patients receiving LATUDA 120 mg/day.  In these short-term trials, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> included: <span class="product-label-link" type="condition" conceptid="438134" conceptname="Hypersomnia">hypersomnia</span>, hypersomnolence, sedation and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>.
</p>
<p>Patients should be cautioned about operating hazardous machinery, including motor vehicles, until they are reasonably certain that therapy with LATUDA does not affect them adversely. 
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e7fdffc2-a5ad-45a1-8ae1-e6001dfc3c18"></a><a name="section-5.11"></a><p></p>
<h2>5.11. Body Temperature Regulation
</h2>
<p class="First">Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents.  Appropriate care is advised when prescribing LATUDA for patients who will be experiencing conditions that may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> <span class="Italics">[see Patient Counseling Information (</span><span class="Italics"><a href="#LINK_27d4a0a3-e721-4d3f-acf0-2d350b079548">17.9</a></span><span class="Italics">)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_47c584b5-fa3a-483b-a1db-32ca93e53c69"></a><a name="section-5.12"></a><p></p>
<h2>5.12. <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span>
</h2>
<p class="First">The possibility of a <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span> is inherent in <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> illness and close supervision of high-risk patients should accompany drug therapy.  Prescriptions for LATUDA should be written for the smallest quantity of tablets consistent with good patient management in order to reduce the risk of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. 
</p>
<p>In short-term, placebo-controlled studies in patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, the incidence of treatment-emergent <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> was 0.6% (6/1004) for LATUDA treated patients compared to 0.4% (2/455) on placebo.  No <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempts</span> or <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">completed suicides</span> were reported in these studies.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_8ce45941-b055-444f-b808-f77d43a2f4fe"></a><a name="section-5.13"></a><p></p>
<h2>5.13. <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span>
</h2>
<p class="First">Esophageal dysmotility and <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> have been associated with antipsychotic drug use. <span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">Aspiration pneumonia</span> is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer's <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. LATUDA is not indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, and should not be used in patients at risk for <span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">aspiration pneumonia</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9585b235-f53d-41b3-ae3e-b3b2d801d895"></a><a name="section-5.14"></a><p></p>
<h2>5.14. Use in Patients with Concomitant Illness
</h2>
<p class="First">Clinical experience with LATUDA in patients with certain concomitant systemic illnesses is limited <span class="Italics">[see Use in Specific Populations (</span><span class="Italics"><a href="#LINK_410f4f2b-4053-41f4-9510-879655a86c86">8.6</a></span><span class="Italics">,
</span><span class="Italics"><a href="#LINK_2c3d9570-f11c-45dd-a9d4-89a403e39d2e">8.7</a></span><span class="Italics">)]</span>.  LATUDA has not been evaluated or used to any appreciable extent in patients with a recent history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or unstable heart disease.  Patients with these diagnoses were excluded from premarketing clinical studies <span class="Italics">[see Warnings and Precautions (</span><span class="Italics"><a href="#LINK_f0eaab5a-ee6c-4115-8951-37cea2c2763b">5.1</a></span><span class="Italics">, <a href="#LINK_2ce5b9e9-505b-44a7-89cc-114eb12eda61">5.8</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_7c7518b1-dcb4-4dd3-96dc-a8cf5d1c285a"></a><a name="section-6"></a><p></p>
<h1>6. ADVERSE REACTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f1ced4c0-d940-47c7-9f2a-e0fe23fda098"></a><a name="section-6.1"></a><p></p>
<h2>6.1. Overall Adverse Reaction Profile
</h2>
<p class="First">The following adverse reactions are discussed in more detail in other sections of the labeling:
</p>
<ul class="Disk">
<li>Use in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span> <span class="Italics">[see <a href="#LINK_48c8dd45-b54e-425d-94ca-27545cd41a23">Boxed Warning</a> and Warnings and Precautions (</span><span class="Italics"><a href="#LINK_f0eaab5a-ee6c-4115-8951-37cea2c2763b">5.1</a></span><span class="Italics">)]</span>
</li>
<li>Cerebrovascular Adverse Reactions, Including <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> <span class="Italics">[see Warnings and Precautions (<a href="#LINK_579b3187-ccf9-4fcd-892e-04091e630a7d">5.2</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> <span class="Italics">[see Warnings and Precautions (<a href="#LINK_9d59ec04-ae9a-4f61-93d2-f8eddd5387d0">5.3</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span> <span class="Italics">[see Warnings and Precautions (<a href="#LINK_aed0ff3c-2d51-4314-83f4-91c9ee97da76">5.4</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus <span class="Italics">[see Warnings and Precautions (<a href="#LINK_91fdf397-0baa-4105-aa32-7d65c78cb7b0">5.5</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">Hyperprolactinemia</span> <span class="Italics">[see Warnings and Precautions (<a href="#LINK_451577ea-5ce4-4f08-89b0-91372b3ded84">5.6</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span> <span class="Italics">[see Warnings and Precautions (<a href="#LINK_122095da-5dfb-4f21-90dd-ec35a78ecf1f">5.7</a></span><span class="Italics">)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span> <span class="Italics">[see Warnings and Precautions (<a href="#LINK_2ce5b9e9-505b-44a7-89cc-114eb12eda61">5.8</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> <span class="Italics">[see Warnings and Precautions (<a href="#LINK_13c948d9-935a-4a05-97c2-009bf3ebb0f0">5.9</a>)]</span>
</li>
<li>Potential for Cognitive and Motor Impairment <span class="Italics">[see Warnings and Precautions (<a href="#LINK_39d6b752-fbbf-434f-bb41-3329ed9c9358">5.10</a>)]</span>
</li>
<li>Body Temperature Regulation <span class="Italics">[see Warnings and Precautions (<a href="#LINK_e7fdffc2-a5ad-45a1-8ae1-e6001dfc3c18">5.11</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> <span class="Italics">[see Warnings and Precautions (<a href="#LINK_47c584b5-fa3a-483b-a1db-32ca93e53c69">5.12</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span> <span class="Italics">[see Warnings and Precautions (<a href="#LINK_8ce45941-b055-444f-b808-f77d43a2f4fe">5.13</a>)]</span>
</li>
<li>Use in Patients with Concomitant Illness <span class="Italics">[see Warnings and Precautions (<a href="#LINK_9585b235-f53d-41b3-ae3e-b3b2d801d895">5.14</a>)]</span>
</li>
</ul>
<p>The information below is derived from a clinical study database for LATUDA consisting of over 2096 patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> exposed to one or more doses with a total experience of 624 patient-years.  Of these patients, 1004 participated in short-term placebo-controlled <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> studies with doses of 20 mg, 40 mg, 80 mg or 120 mg once daily.  A total of 533 LATUDA-treated patients had at least 24 weeks and 238 LATUDA-treated patients had at least 52 weeks of exposure.
</p>
<p>Adverse events during exposure to study treatment were obtained by general inquiry and voluntarily reported adverse experiences, as well as results from physical examinations, vital signs, ECGs, weights and laboratory investigations.  Adverse experiences were recorded by clinical investigators using their own terminology.  In order to provide a meaningful estimate of the proportion of individuals experiencing adverse events, events were grouped in standardized categories using MedDRA terminology.
</p>
<p>The stated frequencies of adverse reactions represent the proportion of individuals who experienced at least once, a treatment-emergent adverse event of the type listed.  Treatment-emergent adverse events were defined as adverse experiences, which started or worsened on or after the date of the first dose through seven days after study medication discontinuation.  There was no attempt to use investigator causality assessments; i.e., all events meeting the defined criteria, regardless of investigator causality are included.  It is important to emphasize that, although the reactions occurred during treatment with LATUDA, they were not necessarily caused by it.  The label should be read in its entirety to gain an understanding of the safety profile of LATUDA.
</p>
<p>The figures in the tables and tabulations cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical studies. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatment, uses and investigators.  The cited figures, however, do provide the prescriber with some basis for estimating the relative contribution of drug and nondrug factors to the adverse reaction incidence in the population studied.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0bfdb801-5e52-4dcc-b22b-d60cdb88d363"></a><a name="section-6.2"></a><p></p>
<h2>6.2. Clinical Studies Experience
</h2>
<p class="First">The following findings are based on the short-term placebo-controlled premarketing studies for <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> in which LATUDA was administered at daily doses ranging from 20 to 120 mg (n = 1004).
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b07142a6-d609-4748-9ea5-360100922f69"></a><a name="section-6.2.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold">Commonly Observed Adverse Reactions:</span> The most common adverse reactions (incidence â‰¥ 5% and at least twice the rate of placebo) in patients treated with LATUDA were <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span> and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3b0377a8-ab90-417a-bb6a-156d9365f812"></a><a name="section-6.2.2"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold">Adverse Reactions Associated with Discontinuation of Treatment:</span> A total of 9.4% (94/1004) LATUDA-treated patients and 5.9% (27/455) of placebo-treated patients discontinued due to adverse reactions. There were no adverse reactions associated with discontinuation in subjects treated with LATUDA that were at least 2% and at least twice the placebo rate.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_032f34e6-42fc-42b9-9651-43ac8a88710b"></a><a name="section-6.2.3"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold">Adverse Reactions Occurring at an Incidence of 2% or More in LATUDA-Treated Patients:</span> Adverse reactions associated with the use of LATUDA (incidence of 2% or greater, rounded to the nearest percent and LATUDA incidence greater than placebo) that occurred during acute therapy (up to 6-weeks in patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>) are shown in Table 6.
</p>
<table>
<caption><span>TableÂ 6: Adverse Reaction in 2% or More of LATUDA-Treated Patients and That Occurred at Greater Incidence than in the Placebo-Treated Patients in Short-term <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> Studies
</span></caption>
<col width="41.819%">
<col width="29.090%">
<col width="29.090%">
<tfoot>
<tr class="First"><td colspan="3" valign="top">Â <p class="First">Note: Figures rounded to the nearest integer
</p>
</td></tr>
<tr><td colspan="3" valign="top">Â <p class="First">* <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> includes adverse event terms: <span class="product-label-link" type="condition" conceptid="438134" conceptname="Hypersomnia">hypersomnia</span>, hypersomnolence, sedation, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>
</p>
</td></tr>
<tr><td colspan="3" valign="top">Â <p class="First">** <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span> includes adverse event terms: <span class="product-label-link" type="condition" conceptid="4161417" conceptname="Bradykinesia">bradykinesia</span>, <span class="product-label-link" type="condition" conceptid="4208094" conceptname="Cogwheel muscle rigidity">cogwheel rigidity</span>, <span class="product-label-link" type="condition" conceptid="4266842" conceptname="Dribbling from mouth">drooling</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal disorder</span>, <span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">hypokinesia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>, <span class="product-label-link" type="condition" conceptid="4160898" conceptname="Motor retardation">psychomotor retardation</span>, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>
</p>
</td></tr>
<tr class="Last"><td colspan="3" valign="top">Â <p class="First">*** <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonia</span> includes adverse event terms: <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, <span class="product-label-link" type="condition" conceptid="4205592" conceptname="Oculogyric crisis">oculogyric crisis</span>, oromandibular <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, tongue spasm, <span class="product-label-link" type="condition" conceptid="440814" conceptname="Torticollis">torticollis</span>, and <span class="product-label-link" type="condition" conceptid="4339090" conceptname="Trismus">trismus</span>
</p>
</td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top">Â </td>
<td class="Toprule" align="center" colspan="2" valign="top">Â <span class="Bold">Percentage of Patients Reporting Reaction</span>
</td>
</tr>
<tr>
<td valign="top">Â <span class="Bold">Body System or Organ Class</span>
</td>
<td align="center" valign="top">Â <span class="Bold">Placebo</span>
</td>
<td align="center" valign="top">Â <span class="Bold">All LATUDA</span>
</td>
</tr>
<tr>
<td class="Botrule" valign="top">Â Â  Â  Â Dictionary-derived Term
</td>
<td class="Botrule" align="center" valign="top">Â <span class="Bold">(N = 455)</span>
</td>
<td class="Botrule" align="center" valign="top">Â <span class="Bold">(N = 1004)</span>
</td>
</tr>
<tr><td colspan="3" valign="top">Â <span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span>
</td></tr>
<tr>
<td valign="top">Â Â  Â  Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>
</td>
<td align="center" valign="top">Â 6
</td>
<td align="center" valign="top">Â 12
</td>
</tr>
<tr>
<td valign="top">Â Â  Â  Â <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>
</td>
<td align="center" valign="top">Â 6
</td>
<td align="center" valign="top">Â 8
</td>
</tr>
<tr>
<td valign="top">Â Â  Â  Â <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span>
</td>
<td align="center" valign="top">Â 6
</td>
<td align="center" valign="top">Â 8
</td>
</tr>
<tr>
<td valign="top">Â Â  Â  Â <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">Salivary hypersecretion</span>
</td>
<td align="center" valign="top">Â &lt;1
</td>
<td align="center" valign="top">Â 2
</td>
</tr>
<tr><td colspan="3" valign="top">Â <span class="Bold">General Disorders and Administration Site Conditions</span>
</td></tr>
<tr>
<td valign="top">Â Â  Â  Â <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>
</td>
<td align="center" valign="top">Â 3
</td>
<td align="center" valign="top">Â 4
</td>
</tr>
<tr><td colspan="3" valign="top">Â <span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span>
</td></tr>
<tr>
<td valign="top">Â Â  Â  Â <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span>
</td>
<td align="center" valign="top">Â 3
</td>
<td align="center" valign="top">Â 4
</td>
</tr>
<tr><td colspan="3" valign="top">Â <span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span>
</td></tr>
<tr>
<td valign="top">Â Â  Â  Â <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>*
</td>
<td align="center" valign="top">Â 10
</td>
<td align="center" valign="top">Â 22
</td>
</tr>
<tr>
<td valign="top">Â Â  Â  Â <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span>
</td>
<td align="center" valign="top">Â 3
</td>
<td align="center" valign="top">Â 15
</td>
</tr>
<tr>
<td valign="top">Â Â  Â  Â <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span>**
</td>
<td align="center" valign="top">Â 5
</td>
<td align="center" valign="top">Â 11
</td>
</tr>
<tr>
<td valign="top">Â Â  Â  Â <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonia</span>***
</td>
<td align="center" valign="top">Â 1
</td>
<td align="center" valign="top">Â 5
</td>
</tr>
<tr>
<td valign="top">Â Â  Â  Â <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>
</td>
<td align="center" valign="top">Â 3
</td>
<td align="center" valign="top">Â 5
</td>
</tr>
<tr><td colspan="3" valign="top">Â <span class="Bold">Psychiatric Disorders</span>
</td></tr>
<tr>
<td valign="top">Â Â  Â  Â <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span>
</td>
<td align="center" valign="top">Â 7
</td>
<td align="center" valign="top">Â 8
</td>
</tr>
<tr>
<td valign="top">Â Â  Â  Â <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span>
</td>
<td align="center" valign="top">Â 3
</td>
<td align="center" valign="top">Â 6
</td>
</tr>
<tr>
<td valign="top">Â Â  Â  Â <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>
</td>
<td align="center" valign="top">Â 3
</td>
<td align="center" valign="top">Â 6
</td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top">Â Â  Â  Â <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span>
</td>
<td class="Botrule" align="center" valign="top">Â 2
</td>
<td class="Botrule" align="center" valign="top">Â 3
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7b365f52-7d8b-4e79-b832-c057a9169fbc"></a><a name="section-6.3"></a><p></p>
<h2>6.3. Dose-Related Adverse Reactions
</h2>
<p class="First">Based on the pooled data from the placebo-controlled, short-term, fixed-dose studies, among the adverse reactions that occurred with a greater than 5% incidence in the patients treated with LATUDA, the apparent dose-related adverse reactions were <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (TableÂ 7).
</p>
<table>
<caption><span>TableÂ 7: Dose-Related Adverse Events
</span></caption>
<col>
<col>
<col>
<col>
<col>
<col>
<thead>
<tr class="First">
<th class="Toprule" valign="top"></th>
<th class="Toprule" align="center" colspan="5" valign="top"><span class="Bold">Percentage of Subjects Reporting Reaction</span></th>
</tr>
<tr class="Last">
<th class="Botrule" valign="top"><span class="Bold">Adverse Event Term</span></th>
<th class="Botrule" align="center" valign="top">
<br><span class="Bold">Placebo</span><br><span class="Bold">(N = 455)</span><br><span class="Bold">(%)</span>
</th>
<th class="Botrule" align="center" valign="top">
<span class="Bold">LATUDA</span><br><span class="Bold">20 mg/day</span><br><span class="Bold">(N = 71)</span><br><span class="Bold">(%)</span>
</th>
<th class="Botrule" align="center" valign="top">
<span class="Bold">LATUDA</span><br><span class="Bold">40 mg/day</span><br><span class="Bold">(N = 360)</span><br><span class="Bold">(%)</span>
</th>
<th class="Botrule" align="center" valign="top">
<span class="Bold">LATUDA</span><br><span class="Bold">80 mg/day</span><br><span class="Bold">(N = 282)</span><br><span class="Bold">(%)</span>
</th>
<th class="Botrule" align="center" valign="top">
<span class="Bold">LATUDA</span><br><span class="Bold">120 mg/day</span><br><span class="Bold">(N = 291)</span><br><span class="Bold">(%)</span>
</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td colspan="6" valign="top">Â <p class="First">Note: Figures rounded to the nearest integer<br>Â  Â  Â * <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> includes adverse event terms: <span class="product-label-link" type="condition" conceptid="438134" conceptname="Hypersomnia">hypersomnia</span>, hypersomnolence, sedation, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>
</p>
</td></tr></tfoot>
<tbody>
<tr class="First">
<td valign="top">Â Â  Â  Â <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span>
</td>
<td align="center" valign="top">Â 3
</td>
<td align="center" valign="top">Â 6
</td>
<td align="center" valign="top">Â 11
</td>
<td align="center" valign="top">Â 15
</td>
<td align="center" valign="top">Â 22
</td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top">Â Â  Â  Â <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>*
</td>
<td class="Botrule" align="center" valign="top">Â 10
</td>
<td class="Botrule" align="center" valign="top">Â 15
</td>
<td class="Botrule" align="center" valign="top">Â 19
</td>
<td class="Botrule" align="center" valign="top">Â 23
</td>
<td class="Botrule" align="center" valign="top">Â 26
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_095d668d-d5bc-48b8-9403-4b2898193349"></a><a name="section-6.4"></a><p></p>
<h2>6.4. <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal Symptoms</span>
</h2>
<p class="First">In the short-term, placebo-controlled <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> studies, for LATUDA-treated patients, the incidence of reported EPS-related events, excluding <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> and <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, was 14.7% versus 5.1% for placebo-treated patients; and the incidence of <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> for LATUDA-treated patients was 15.0% versus 3.3% for placebo-treated patients.  <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span> appeared to be dose-related and the greatest frequency of <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span> and <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span> occurred with the highest dose of LATUDA, 120 mg/day (Table 8).
</p>
<table>
<caption><span>TableÂ 8: Percentage of EPS Compared to Placebo
</span></caption>
<col>
<col>
<col>
<col>
<col>
<col>
<thead>
<tr class="First">
<th class="Botrule" valign="top"><span class="Bold">Adverse Event Term</span></th>
<th class="Botrule" align="center" valign="top">
<br><span class="Bold">Placebo</span><br><span class="Bold">(N = 455)</span><br><span class="Bold">(%)</span>
</th>
<th class="Botrule" align="center" valign="top">
<span class="Bold">LATUDA</span><br><span class="Bold">20 mg/day</span><br><span class="Bold">(N = 71)</span><br><span class="Bold">(%)</span>
</th>
<th class="Botrule" align="center" valign="top">
<span class="Bold">LATUDA</span><br><span class="Bold">40 mg/day</span><br><span class="Bold">(N = 360)</span><br><span class="Bold">(%)</span>
</th>
<th class="Botrule" align="center" valign="top">
<span class="Bold">LATUDA</span><br><span class="Bold">80 mg/day</span><br><span class="Bold">(N = 282)</span><br><span class="Bold">(%)</span>
</th>
<th class="Botrule" align="center" valign="top">
<span class="Bold">LATUDA</span><br><span class="Bold">120 mg/day</span><br><span class="Bold">(N = 291)</span><br><span class="Bold">(%)</span>
</th>
</tr>
<tr>
<th class="Botrule" valign="top"><span class="Bold">All EPS events</span></th>
<th class="Botrule" align="center" valign="top"> 9
</th>
<th class="Botrule" align="center" valign="top"> 10
</th>
<th class="Botrule" align="center" valign="top"> 24
</th>
<th class="Botrule" align="center" valign="top"> 26
</th>
<th class="Botrule" align="center" valign="top"> 39
</th>
</tr>
<tr class="Last">
<th class="Botrule" valign="top"><span class="Bold">All EPS events, excluding <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span>/<span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span></span></th>
<th class="Botrule" align="center" valign="top"> 5
</th>
<th class="Botrule" align="center" valign="top"> 6
</th>
<th class="Botrule" align="center" valign="top"> 13
</th>
<th class="Botrule" align="center" valign="top"> 11
</th>
<th class="Botrule" align="center" valign="top"> 22
</th>
</tr>
</thead>
<tfoot>
<tr class="First"><td colspan="6" valign="top">Â <p class="First">Note: Figures rounded to the nearest integer
</p>
</td></tr>
<tr><td colspan="6" valign="top">Â <p class="First">* <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonia</span> includes adverse event terms: <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, <span class="product-label-link" type="condition" conceptid="4205592" conceptname="Oculogyric crisis">oculogyric crisis</span>, oromandibular <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, tongue spasm, <span class="product-label-link" type="condition" conceptid="440814" conceptname="Torticollis">torticollis</span>, and <span class="product-label-link" type="condition" conceptid="4339090" conceptname="Trismus">trismus</span>
</p>
</td></tr>
<tr class="Last"><td colspan="6" valign="top">Â <p class="First">** <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span> includes adverse event terms: <span class="product-label-link" type="condition" conceptid="4161417" conceptname="Bradykinesia">bradykinesia</span>, <span class="product-label-link" type="condition" conceptid="4208094" conceptname="Cogwheel muscle rigidity">cogwheel rigidity</span>, <span class="product-label-link" type="condition" conceptid="4266842" conceptname="Dribbling from mouth">drooling</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal disorder</span>, <span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">hypokinesia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>, <span class="product-label-link" type="condition" conceptid="4160898" conceptname="Motor retardation">psychomotor retardation</span>, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>
</p>
</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td valign="top">Â Â  Â  Â <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span>
</td>
<td align="center" valign="top">Â 3
</td>
<td align="center" valign="top">Â 6
</td>
<td align="center" valign="top">Â 11
</td>
<td align="center" valign="top">Â 15
</td>
<td align="center" valign="top">Â 22
</td>
</tr>
<tr>
<td valign="top">Â Â  Â  Â <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonia</span>*
</td>
<td align="center" valign="top">Â 1
</td>
<td align="center" valign="top">Â 0
</td>
<td align="center" valign="top">Â 4
</td>
<td align="center" valign="top">Â 5
</td>
<td align="center" valign="top">Â 7
</td>
</tr>
<tr>
<td valign="top">Â Â  Â  Â <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span>**
</td>
<td align="center" valign="top">Â 5
</td>
<td align="center" valign="top">Â 6
</td>
<td align="center" valign="top">Â 10
</td>
<td align="center" valign="top">Â 7
</td>
<td align="center" valign="top">Â 17
</td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top">Â Â  Â  Â <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span>
</td>
<td class="Botrule" align="center" valign="top">Â 2
</td>
<td class="Botrule" align="center" valign="top">Â 1
</td>
<td class="Botrule" align="center" valign="top">Â 4
</td>
<td class="Botrule" align="center" valign="top">Â 1
</td>
<td class="Botrule" align="center" valign="top">Â 3
</td>
</tr>
</tbody>
</table>
<p>In the short-term, placebo-controlled <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> studies, data was objectively collected on the Simpson Angus Rating Scale for <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> (EPS), the Barnes <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span> Scale (for <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>) and the Abnormal Involuntary Movement Scale (for <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesias</span>).  The mean change from baseline for LATUDA-treated patients was comparable to placebo-treated patients, with the exception of the Barnes <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span> Scale global score (LATUDA, 0.2; placebo, 0.0).  The percentage of patients who shifted from normal to abnormal was greater in LATUDA-treated patients versus placebo for the BAS (LATUDA, 16.0%; placebo, 7.6%) and the SAS (LATUDA, 5.3%; placebo, 2.5%). 
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6be00f52-8c84-4473-82c2-ecd397597305"></a><a name="section-6.4.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonia</span></span></p>
<p><span class="Italics">Class Effect:</span> Symptoms of <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment.  Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, and/or protrusion of the tongue.  While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">acute dystonia</span> is observed in males and younger age groups.
</p>
<p>In the short-term, placebo-controlled clinical trials, <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span> occurred in 4.7% of LATUDA-treated subjects (0.0% LATUDA 20 mg, 4.2% LATUDA 40 mg, 4.6% LATUDA 80 mg and 6.5% LATUDA 120 mg) compared to  0.7% of subjects receiving placebo.  Seven subjects (0.7%, 7/1004) discontinued clinical trials due to dystonic events â€“ 4 were receiving LATUDA 80 mg/day and 3 were receiving LATUDA 120 mg/day.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6668503f-efe3-4481-bdb7-9e018e599939"></a><a name="section-6.5"></a><p></p>
<h2>6.5. Laboratory Test Abnormalities and ECG Changes in Clinical Studies
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3a0bac12-77dd-43cd-bcc0-c936f07a0d76"></a><a name="section-6.5.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold">Laboratory Test Abnormalities</span></p>
<p>In a between-group comparison of the pooled data from short-term, placebo-controlled studies, there were no clinically important changes in total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> measurements; triglycerides or glucose from Baseline to Endpoint [<span class="Italics">see Warnings and Precautions</span> (<span class="Italics"><a href="#LINK_91fdf397-0baa-4105-aa32-7d65c78cb7b0">5.5</a></span><span class="Italics">)</span>].  There were also no clinically important differences between LATUDA and placebo in mean change from baseline to endpoint in routine hematology, urinalysis, or serum chemistry.  LATUDA was associated with a dose-related increase in prolactin concentration [<span class="Italics">see Warnings and Precautions</span> (<span class="Italics"><a href="#LINK_451577ea-5ce4-4f08-89b0-91372b3ded84">5.6</a></span><span class="Italics">)</span>]
</p>
<p><span class="Italics">Creatinine</span>: In short-term, placebo-controlled trials, the mean change from Baseline in creatinine was 0.06 mg/dL for LATUDA-treated patients compared to 0.03 mg/dL for placebo-treated patients. A creatinine shift from normal to high occurred in 3.1% (30/977) of LATUDA-treated patients and 1.4% (6/439) on placebo.  The threshold for high creatinine value varied from â‰¥ 1.1 to â‰¥ 1.3 mg/dL based on the centralized laboratory definition for each study [<span class="Italics">see Dosage in Special Population (</span><span class="Italics"><a href="#LINK_d69a7bb8-3c47-4720-b0cc-34ca02c30ba1">2.3</a></span><span class="Italics">); Use in Specific Populations (</span><span class="Italics"><a href="#LINK_437f91ce-1c25-42a6-98c6-508ae49fdc24">8</a></span><span class="Italics">)].</span></p>
<p><span class="Italics">Transaminases:</span> The mean changes in AST and ALT for LATUDA- and placebo-treated patients were similar.  The proportion of patients with transaminases (AST and ALT) elevations â‰¥ 3 times ULN was similar for all LATUDA-treated patients (0.8% and 0.8%, respectively) to placebo-treated patients (0.9% and 1.1%, respectively). 
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_697c32b3-9af9-43c8-9e12-2dd7104203ff"></a><a name="section-6.5.2"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold">ECG Changes</span></p>
<p>Electrocardiogram (ECG) measurements were taken at various time points during the LATUDA clinical trial program. No post-baseline QT prolongations exceeding 500 msec were reported in patients treated with LATUDA.  Within a subset of patients defined as having an increased cardiac risk, no potentially important changes in ECG parameters were observed.  No cases of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span> or other severe <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> were observed in the pre-marketing clinical program.
</p>
<p>The effects of LATUDA on the QT/QTc interval were evaluated in a dedicated QT study involving 87 clinically stable patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> or <span class="product-label-link" type="condition" conceptid="4286201" conceptname="Schizoaffective disorder">schizoaffective disorder</span>, who were treated with LATUDA doses of 120 mg daily, 600 mg daily, or ziprasidone 160 mg daily.  Holter monitor-derived electrocardiographic assessments were obtained over an eight hour period at baseline and steady state. No patients treated with LATUDA experienced QTc increases &gt; 60 msec from baseline, nor did any patient experience a QTc of &gt; 500 msec.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_1c4b542d-ed65-46b8-a7e1-3aa57075247c"></a><a name="section-6.6"></a><p></p>
<h2>6.6. Other Adverse Reactions Observed During the Premarketing Evaluation of LATUDA
</h2>
<p class="First">Following is a list of MedDRA terms that reflect adverse reactions reported by patients treated with LATUDA at multiple doses of â‰¥ 20 mg once daily during any phase of a study within the database of 2096 patients. The reactions listed are those that could be of clinical importance, as well as reactions that are plausibly drug-related on pharmacologic or other grounds.  Reactions listed in Table 6 are not included. Although the reactions reported occurred during treatment with LATUDA, they were not necessarily caused by it. 
</p>
<p>Reactions are further categorized by MedDRA system organ class and listed in order of decreasing frequency according to the following definitions: those occurring in at least 1/100 patients (frequent) (only those not already listed in the tabulated results from placebo-controlled studies appear in this listing); those occurring in 1/100 to 1/1000 patients (infrequent); and those occurring in fewer than 1/1000 patients (rare).
</p>
<p><span class="Italics"><span class="Underline">Blood and Lymphatic System Disorders:
</span></span><span class="Bold"><span class="Italics">Infrequent:
</span></span><span class="Italics"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>;
</span><span class="Bold"><span class="Italics">Rare:
</span></span><span class="Italics"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span></span></p>
<p><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span>:
</span></span><span class="Bold"><span class="Italics">Frequent:
</span></span><span class="Italics"><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>;
</span><span class="Bold"><span class="Italics">Infrequent:
</span></span><span class="Italics"><span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> 1st degree, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span></span></p>
<p><span class="Italics"><span class="Underline">Ear and Labyrinth Disorders</span></span>: <span class="Bold"><span class="Italics">Infrequent:
</span></span><span class="Italics"><span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span></span></p>
<p><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorders</span>:
</span></span><span class="Bold"><span class="Italics">Frequent:
</span></span><span class="Italics"><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span></span></p>
<p><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>:
</span></span><span class="Bold"><span class="Italics">Frequent:
</span></span><span class="Italics"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>;
</span><span class="Bold"><span class="Italics">Infrequent:
</span></span><span class="Italics"><span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span></span></p>
<p><span class="Italics"><span class="Underline">General Disorders and Administrative Site Conditions</span></span>: <span class="Bold"><span class="Italics">Rare</span></span><span class="Italics">: <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">Sudden death</span></span></p>
<p><span class="Italics"><span class="Underline">Investigations:
</span></span><span class="Bold"><span class="Italics">Frequent:
</span></span><span class="Italics">CPK increased</span></p>
<p><span class="Italics"><span class="Underline">Metabolic and Nutritional System Disorders:
</span></span><span class="Bold"><span class="Italics">Frequent:
</span></span><span class="Italics"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span></span></p>
<p><span class="Italics"><span class="Underline">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span>:
</span></span><span class="Bold"><span class="Italics">Rare:
</span></span><span class="Italics"><span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span></span></p>
<p><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>:
</span></span><span class="Bold"><span class="Italics">Infrequent</span></span>: <span class="Italics"><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span></span>; <span class="Bold"><span class="Italics">Rare:
</span></span><span class="Italics"><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">neuroleptic malignant syndrome</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span></span></p>
<p><span class="Italics"><span class="Underline">Psychiatric Disorders:
</span></span><span class="Bold"><span class="Italics">Infrequent:
</span></span><span class="Italics"><span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">abnormal dreams</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attack</span>, <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorder</span>;
</span><span class="Bold"><span class="Italics">Rare:
</span></span><span class="Italics"><span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span></span></p>
<p><span class="Italics"><span class="Underline">Renal and Urinary Disorders</span></span>: <span class="Bold"><span class="Italics">Infrequent:
</span></span><span class="Italics"><span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>;
</span><span class="Bold"><span class="Italics">Rare:
</span></span><span class="Italics"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span></span></p>
<p><span class="Italics"><span class="Underline">Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span>:
</span></span><span class="Bold"><span class="Italics">Infrequent:
</span></span><span class="Italics"><span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>;
</span><span class="Bold"><span class="Italics">Rare:
</span></span><span class="Italics"><span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>, <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span>, <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span></span></p>
<p><span class="Italics"><span class="Underline">Skin and Subcutaneous Tissue Disorders:
</span></span><span class="Bold"><span class="Italics">Frequent:
</span></span><span class="Italics"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></span>; <span class="Bold"><span class="Italics">Rare:
</span></span><span class="Italics"><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span></span></p>
<p><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span>:
</span></span><span class="Bold"><span class="Italics">Infrequent:
</span></span><span class="Italics"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_605c9ec5-aaa8-4e40-8c8b-acb62c67cd39"></a><a name="section-7"></a><p></p>
<h1>7. DRUG INTERACTIONS
</h1>
<p class="First">Given the primary CNS effects of LATUDA, caution should be used when it is taken in combination with other centrally acting drugs and alcohol. 
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_baf95071-f5f0-4ae0-8eaf-8ae11def24b5"></a><a name="section-7.1"></a><p></p>
<h2>7.1. Potential for Other Drugs to Affect LATUDA
</h2>
<p class="First">LATUDA is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP4A11, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP2E1 enzymes. This suggests that an interaction of LATUDA with drugs that are inhibitors or inducers of these enzymes is unlikely.
</p>
<p>LATUDA is predominantly metabolized by CYP3A4; interaction of LATUDA with strong and moderate inhibitors or inducers of this enzyme has been observed (TableÂ 9).  LATUDA should not be used in combination with strong inhibitors or inducers of this enzyme <span class="Italics">[see Contraindications (</span><span class="Italics"><a href="#LINK_b4712740-0b8e-437d-97a0-fe8509a0b283">4</a></span><span class="Italics">)].</span></p>
<table>
<caption><span>TableÂ 9: Summary of Effect of Coadministered Drugs on Exposure to LATUDA in Healthy Subjects or Patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span>
</span></caption>
<col width="27.655%">
<col width="15.769%">
<col width="13.452%">
<col width="11.419%">
<col width="13.802%">
<col width="17.903%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top">Â <span class="Bold">Coadministered drug</span>
</td>
<td class="Botrule Toprule" align="center" colspan="2" valign="top">Â <span class="Bold">Dose schedule</span>
</td>
<td class="Botrule Toprule" align="center" colspan="2" valign="top">Â <span class="Bold">Effect on LATUDA pharmacokinetics</span>
</td>
<td class="Toprule" align="center" valign="top">Â <span class="Bold">Recommendation</span>
</td>
</tr>
<tr>
<td class="Botrule" valign="top">Â </td>
<td class="Botrule" align="center" valign="top">Â <span class="Bold">Coadministered drug</span>
</td>
<td class="Botrule" align="center" valign="top">Â <span class="Bold">LATUDA</span>
</td>
<td class="Botrule" align="center" valign="top">Â <span class="Bold">C</span><span class="Sub">max</span>
</td>
<td class="Botrule" align="center" valign="top">Â <span class="Bold">AUC</span>
</td>
<td class="Botrule" align="center" valign="top">Â </td>
</tr>
<tr>
<td class="Botrule" valign="top">Â <span class="Bold">Ketoconazole </span><br><span class="Bold">(strong CYP3A4 inhibitor)</span><br>
</td>
<td class="Botrule" align="center" valign="top">Â 400 mg/day<br>for 5 days
</td>
<td class="Botrule" align="center" valign="top">Â 10 mg<br>single dose
</td>
<td class="Botrule" align="center" valign="top">Â 6.9-times <br>LATUDA alone
</td>
<td class="Botrule" align="center" valign="top">Â 9-times <br>LATUDA  alone
</td>
<td class="Botrule" valign="top">Â Should not be coadministered with LATUDA
</td>
</tr>
<tr>
<td class="Botrule" valign="top">Â <span class="Bold">Diltiazem</span><br><span class="Bold">(moderate CYP3A4 inhibitor)</span><br>
</td>
<td class="Botrule" align="center" valign="top">Â 240 mg/ day<br>for 5 days
</td>
<td class="Botrule" align="center" valign="top">Â 20 mg<br>single dose
</td>
<td class="Botrule" align="center" valign="top">Â 2.1- times <br>LATUDA alone
</td>
<td class="Botrule" align="center" valign="top">Â 2.2- times <br>LATUDA  alone
</td>
<td class="Botrule" valign="top">Â LATUDA dose should not exceed 40 mg/day if coadministered   
</td>
</tr>
<tr>
<td class="Botrule" valign="top">Â <span class="Bold">Rifampin</span><br><span class="Bold">(strong CYP3A4 inducer)</span><br>
</td>
<td class="Botrule" align="center" valign="top">Â 600 mg/day<br>for 8 days
</td>
<td class="Botrule" align="center" valign="top">Â 40 mg<br>single dose
</td>
<td class="Botrule" align="center" valign="top">Â 1/7<span class="Sup">th</span> of LATUDA alone 
</td>
<td class="Botrule" align="center" valign="top">Â 1/5<span class="Sup">th</span> of LATUDA  alone
</td>
<td class="Botrule" valign="top">Â Should not be coadministered with LATUDA
</td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top">Â <span class="Bold">Lithium</span><br>
</td>
<td class="Botrule" align="center" valign="top">Â 600 mg BID<br>for 8 days
</td>
<td class="Botrule" align="center" valign="top">Â 120 mg/day<br>for 8 days
</td>
<td class="Botrule" align="center" valign="top">Â 0.9-times LATUDA alone 
</td>
<td class="Botrule" align="center" valign="top">Â 1.1- times LATUDA  alone 
</td>
<td class="Botrule" valign="top">Â No LATUDA dose adjustment required.
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2c145bac-572e-4f64-989d-1f30c48f8174"></a><a name="section-7.2"></a><p></p>
<h2>7.2. Potential for LATUDA to Affect Other Drugs
</h2>
<p class="First"><span class="Bold">Digoxin (P-gp substrate):</span>  Coadministration of LATUDA (120 mg/day) at steady state with a single dose of digoxin (0.25 mg) increased C<span class="Sub">max</span> and AUC<span class="Sub">(0-24)</span> for digoxin by approximately 9% and 13%, respectively relative to digoxin alone.  Digoxin dose adjustment is not required when coadministered with LATUDA.
</p>
<p><span class="Bold">Midazolam (CYP3A4 substrate):</span> Coadministration of LATUDA (120 mg/day) at steady state with a single dose of 5 mg midazolam increased midazolam Cmax and AUC<span class="Sub">(0-24)</span> by approximately 21% and 44%, respectively relative to midazolam alone.  Midazolam dose adjustment is not required when coadministered with LATUDA.
</p>
<p><span class="Bold">Oral Contraceptive (estrogen/progesterone):</span> Coadministration of LATUDA (40 mg/day) at steady state with an oral contraceptive (OC) containing ethinyl estradiol and norelgestimate resulted in equivalent AUC<span class="Sub">(0-24)</span> and C<span class="Sub">max</span> of ethinyl estradiol and norelgestromin relative to OC administration alone.  Also, <span class="product-label-link" type="condition" conceptid="4206320" conceptname="Sex steroid binding globulin">sex hormone binding globulin</span> levels were not meaningfully affected by coadministration of LATUDA and OC. Dose adjustment of OC dose is not required when coadministered with LATUDA. 
</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="LINK_437f91ce-1c25-42a6-98c6-508ae49fdc24"></a><a name="section-8"></a><p></p>
<h1>8. USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_c20e55f7-c404-41eb-81a7-59d2a6be3975"></a><a name="section-8.1"></a><p></p>
<h2>8.1. Pregnancy
</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="LINK_1a0d8f61-fd1c-46fd-a713-13ecf24e9d5c"></a><a name="section-8.1.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold">Teratogenic Effects</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_cf2712da-8b08-4b11-b044-8e5dc7c2ef1a"></a><a name="section-8.1.1.1"></a><p></p>
<h4></h4>
<p class="First">Pregnancy Category B
</p>
<p>Lurasidone was not teratogenic in rats and rabbits. There are no adequate and well-controlled studies of LATUDA in pregnant women.
</p>
<p>No teratogenic effects were seen in studies in which pregnant rats and rabbits were given lurasidone during the period of organogenesis at doses up to 25 and 50 mg/kg/day, respectively.  These doses are 3 and 12 times, in rats and rabbits respectively, the maximum recommended human dose (MRHD) of 80 mg/day based on body surface area.
</p>
<p>No adverse developmental effects were seen in a study in which pregnant rats were given lurasidone during the period of organogenesis and continuing through weaning at doses up to 10 mg/kg/day; this dose is approximately equal to the MRHD based on body surface area.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="LINK_9d643761-085d-485e-9e23-ee9010f52619"></a><a name="section-8.1.2"></a><p></p>
<h3></h3>
<p class="First"><span class="Bold">Non-teratogenic Effects</span></p>
<p>Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery.  There have been reports of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> and <span class="product-label-link" type="condition" conceptid="434750" conceptname="Feeding difficulties and mismanagement">feeding disorder</span> in these neonates.  These complications have varied in severity; while in some cases symptoms have been self-limited, in other cases neonates have required intensive care unit support and prolonged hospitalization.
</p>
<p>LATUDA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="LINK_a53f39a1-fe0e-4ef8-8523-b174b3b2f871"></a><a name="section-8.2"></a><p></p>
<h2>8.2. Labor and Delivery
</h2>
<p class="First">The effect of LATUDA on labor and delivery in humans is unknown.
</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_b533c6dd-4bc7-4d8e-9412-41b568d7c5d5"></a><a name="section-8.3"></a><p></p>
<h2>8.3. Nursing Mothers
</h2>
<p class="First">LATUDA was excreted in milk of rats during lactation.  It is not known whether LATUDA or its metabolites are excreted in human milk.  Breast feeding in women receiving LATUDA should be considered only if the potential benefit justifies the potential risk to the child. 
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_8e2056b4-5332-498b-b5e6-4b6872a16530"></a><a name="section-8.4"></a><p></p>
<h2>8.4. Pediatric Use
</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established. 
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_288d771e-8a3b-44da-b5d1-f87bc9c26166"></a><a name="section-8.5"></a><p></p>
<h2>8.5. Geriatric Use
</h2>
<p class="First">Clinical studies of LATUDA in the treatment of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> did not include sufficient numbers of patients aged 65 and older to determine whether or not they respond differently from younger patients.  In elderly patients with <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> (65 to 85), lurasidone concentrations (20 mg/day) were similar to those in young subjects <span class="Italics">[see Clinical Pharmacology (</span><span class="Italics"><a href="#LINK_300c0990-4014-4a74-b228-8ab3bf94373e">12.3</a></span><span class="Italics">)]</span>.  No dose adjustment is necessary in elderly patients.
</p>
<p>Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with LATUDA are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> compared to placebo.  LATUDA is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> <span class="Italics">[see <a href="#LINK_48c8dd45-b54e-425d-94ca-27545cd41a23">Boxed Warning</a>]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_410f4f2b-4053-41f4-9510-879655a86c86"></a><a name="section-8.6"></a><p></p>
<h2>8.6. <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</h2>
<p class="First">It is recommended that LATUDA dose should not exceed 40 mg/day in patients with moderate and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (Cl<span class="Sub">cr</span> â‰¥ 10 mL/min to &lt; 50 mL/min).
</p>
<p>After administration of a single dose of 40 mg LATUDA to patients with mild, moderate and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, mean C<span class="Sub">max</span> increased by 40%, 92% and 54%, respectively and mean AUC<span class="Sub">(0-âˆž)</span> increased by 53%, 91% and 2- times, respectively compared to healthy matched subjects.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2c3d9570-f11c-45dd-a9d4-89a403e39d2e"></a><a name="section-8.7"></a><p></p>
<h2>8.7. <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</h2>
<p class="First">It is recommended that LATUDA dose should not exceed 40 mg/day in patients with moderate and severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class B and C).  In a single-dose study of LATUDA 20 mg, lurasidone mean AUC<span class="Sub">(0-last)</span> was 1.5-times higher in subjects with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class A), 1.7-times higher in subjects with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class B) and 3-times higher in subjects with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class C) compared to the values for healthy matched subjects.  Mean C<span class="Sub">max</span> was 1.3, 1.2 and 1.3-times higher for mild, moderate and severe hepatically impaired patients respectively, compared to the values for healthy matched subjects.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_515f8fc2-db60-446c-9ccf-b11d77c6c9c0"></a><a name="section-8.8"></a><p></p>
<h2>8.8. Gender
</h2>
<p class="First">Population pharmacokinetic evaluation indicated that the mean AUC of LATUDA was 18% higher in women than in men, and correspondingly, the apparent oral clearance of LATUDA was lower in women.  Mean C<span class="Sub">max</span> of LATUDA was similar between women and men.  No dosage adjustment of LATUDA is recommended based on gender.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_40795a37-3797-49ff-a3f3-b5ae897e42d2"></a><a name="section-8.9"></a><p></p>
<h2>8.9. Race
</h2>
<p class="First">Although no specific pharmacokinetic study was conducted to investigate the effects of race on the disposition of LATUDA, population pharmacokinetic evaluation revealed no evidence of clinically significant race-related differences in the pharmacokinetics of LATUDA.  No dosage adjustment of LATUDA is recommended based on race.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d11eca14-230d-4126-a067-5dfdb607089a"></a><a name="section-8.10"></a><p></p>
<h2>8.10. Smoking Status
</h2>
<p class="First">Based on in vitro studies utilizing human liver enzymes, LATUDA is not a substrate for CYP1A2; smoking is therefore not expected to have an effect on the pharmacokinetics of LATUDA.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="LINK_fbabbc16-a2f4-4054-9728-501856e425e4"></a><a name="section-9"></a><p></p>
<h1>9. DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span>
</h1>
<div class="Section" data-sectionCode="34085-1">
<a name="LINK_3e5005e0-16bc-496d-b6f7-1d0f806b5542"></a><a name="section-9.1"></a><p></p>
<h2>9.1. Controlled substance
</h2>
<p class="First">LATUDA is not a controlled substance. 
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6a3ae865-8b7d-47b2-af1e-60b8a3026c80"></a><a name="section-9.2"></a><p></p>
<h2>9.2. Abuse
</h2>
<p class="First">LATUDA has not been systematically studied in humans for its potential for abuse or physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> or its ability to induce tolerance.  While clinical studies with LATUDA did not reveal any tendency for drug-seeking behavior, these observations were not systematic and it is not possible to predict the extent to which a CNS-active drug will be misused, diverted and/or abused once it is marketed.  Patients should be evaluated carefully for a history of drug abuse, and such patients should be observed carefully for signs of LATUDA misuse or abuse (e.g., development of tolerance, drug-seeking behavior, increases in dose). 
</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_604f1ea5-55c8-4a8c-bb0f-c552b5c8cdb8"></a><a name="section-10"></a><p></p>
<h1>10. OVERDOSAGE
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_5dee3606-d5b0-4d60-9b4b-640f8706d396"></a><a name="section-10.1"></a><p></p>
<h2>10.1. Human Experience
</h2>
<p class="First">In premarketing clinical studies involving more than 2096 patients and/or healthy subjects, accidental or intentional overdosage of LATUDA was identified in one patient who ingested an estimated 560 mg of LATUDA.  This patient recovered without sequelae.  This patient resumed LATUDA treatment for an additional two months.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6902e81c-4efe-4057-8d3f-9f2bf7352bfb"></a><a name="section-10.2"></a><p></p>
<h2>10.2. Management of Overdosage
</h2>
<p class="First">Consult a Certified Poison Control Center for up-to-date guidance and advice.  There is no specific antidote to LATUDA, therefore, appropriate supportive measures should be instituted and close medical supervision and monitoring should continue until the patient recovers. 
</p>
<p>Cardiovascular monitoring should commence immediately, including continuous electrocardiographic monitoring for possible <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>.  If antiarrhythmic therapy is administered, disopyramide, procainamide, and quinidine carry a theoretical hazard of additive QT-prolonging effects when administered in patients with an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdose</span> of LATUDA.  Similarly the alpha-blocking properties of bretylium might be additive to those of LATUDA, resulting in problematic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.
</p>
<p><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span> should be treated with appropriate measures.  Epinephrine and dopamine should not be used, or other sympathomimetics with beta-agonist activity, since beta stimulation may worsen <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in the setting of LATUDA-induced alpha blockade.  In case of severe <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span>, anticholinergic medication should be administered. 
</p>
<p>Gastric lavage (after intubation if patient is <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconscious</span>) and administration of activated charcoal together with a laxative should be considered.
</p>
<p>The possibility of <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">obtundation</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, or <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonic reaction</span> of the head and neck following <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may create a risk of <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> with induced <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>.   
</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_098bd21c-991b-4b35-81f5-2b167431f349"></a><a name="section-11"></a><p></p>
<h1>11. DESCRIPTION</h1>
<p class="First">LATUDA is a psychotropic agent belonging to the chemical class of benzoisothiazol derivatives. </p>
<p>Its chemical name is (3a<span class="Italics">R</span>,4<span class="Italics">S</span>,7<span class="Italics">R</span>,7a<span class="Italics">S</span>)-2-{(1<span class="Italics">R</span>,2<span class="Italics">R</span>)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl] cyclohexylmethyl}hexahydro-4,7-methano-2<span class="Italics">H</span>-isoindole-1,3-dione hydrochloride. Its molecular formula is C<span class="Sub">28</span>H<span class="Sub">36</span>N<span class="Sub">4</span>O<span class="Sub">2</span>SÂ·HCl and its molecular weight is 529.14. </p>
<p>The chemical structure is: <br><br><img alt="chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=88a244d1-eddb-499c-bee2-e1f49056e78f&amp;name=lurasidone-hydrochloride-1.jpg"></p>
<p>Lurasidone hydrochloride is a white to off-white powder. It is very slightly soluble in water, practically insoluble or insoluble in 0.1 N HCl, slightly soluble in ethanol, sparingly soluble in methanol, practically insoluble or insoluble in toluene and very slightly soluble in acetone. </p>
<p>LATUDA tablets are intended for oral administration only. Each tablet contains 40 mg, or 80 mg of lurasidone hydrochloride. </p>
<p>Inactive ingredients are mannitol, pregelatinized starch, croscarmellose sodium, hypromellose, magnesium stearate, OpadryÂ® and carnauba wax. Additionally, the 80 mg tablet contains yellow ferric oxide and FD&amp;C Blue No.2 Aluminum Lake. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_1312e395-defc-4f97-8c14-ccbbfef1ac79"></a><a name="section-12"></a><p></p>
<h1>12. CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="LINK_c4933414-0dcd-4076-b748-32e7c5a30a3e"></a><a name="section-12.1"></a><p></p>
<h2>12.1. Mechanism of Action
</h2>
<p class="First">The mechanism of action of lurasidone, as with other drugs having efficacy in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, is unknown.  It has been suggested that the efficacy of lurasidone in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> is mediated through a combination of central dopamine Type 2 (D<span class="Sub">2</span>) and serotonin Type 2 (5HT<span class="Sub">2A</span>) receptor antagonism.
</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="LINK_51d6cb8b-7252-49e8-87f1-d295c2610ed4"></a><a name="section-12.2"></a><p></p>
<h2>12.2. Pharmacodynamics
</h2>
<p class="First">In vitro receptor binding studies revealed that lurasidone is an antagonist with high affinity at dopamine D<span class="Sub">2</span> receptors (Ki = 0.994 nM) and the 5-hydroxytryptamine (5-HT, serotonin) receptors 5-HT<span class="Sub">2A</span> (Ki = 0.47 nM) and 5-HT<span class="Sub">7</span> (Ki = 0.495 nM), is an antagonist with moderate affinity at human Î±<span class="Sub">2C</span> adrenergic receptors (Ki = 10.8 nM), is a partial agonist at serotonin 5-HT<span class="Sub">1A</span> (Ki = 6.38 nM) receptors, and is an antagonist at Î±<span class="Sub">2A</span> adrenergic receptors (Ki = 40.7 nM).  Lurasidone exhibits little or no affinity for histamine H<span class="Sub">1</span> and muscarinic M<span class="Sub">1</span> receptors (IC<span class="Sub">50</span> â‰¥ 1,000 nM and &gt; 1,000 nM, respectively).
</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_300c0990-4014-4a74-b228-8ab3bf94373e"></a><a name="section-12.3"></a><p></p>
<h2>12.3. Pharmacokinetics
</h2>
<p class="First">The activity of lurasidone is primarily due to the parent drug.  The pharmacokinetics of lurasidone is dose-proportional within a total daily dose range of 20 mg to 160 mg.  Steady-state concentrations of lurasidone are reached within 7 days of starting LATUDA. 
</p>
<p>Following administration of 40 mg of LATUDA, the mean (%CV) elimination half-life was 18 (7) hours.  
</p>
<p><span class="Bold">Absorption and Distribution:</span> Lurasidone is absorbed and reaches peak serum concentrations in approximately 1-3 hours.  It is estimated that 9-19% of an administered dose is absorbed.  Following administration of 40 mg of LATUDA, the mean (%CV) apparent volume of distribution was 6173 (17.2) L.  Lurasidone is highly bound (~99%) to serum proteins.
</p>
<p>In a food effect study, lurasidone mean C<span class="Sub">max</span> and AUC were about 3-times and 2-times, respectively, when administered with food compared to the levels observed under fasting conditions.  Lurasidone exposure was not affected as meal size was increased from 350 to 1000 calories and was independent of meal fat content [see <span class="Italics">Dosage and Administration (</span><span class="Italics"><a href="#LINK_c5001172-25d4-4d1e-9c30-05cb3b59d031">2.2</a></span><span class="Italics">)</span>].
</p>
<p>In clinical studies, establishing the safety and efficacy of LATUDA, patients were instructed to take their daily dose with food [<span class="Italics">see Dosage and Administration (</span><span class="Italics"><a href="#LINK_c5001172-25d4-4d1e-9c30-05cb3b59d031">2.2</a></span><span class="Italics">)</span>].
</p>
<p><span class="Bold">Metabolism and Elimination</span>: Lurasidone is metabolized mainly via CYP3A4. The major biotransformation pathways are oxidative <span class="Italics">N</span>-dealkylation, hydroxylation of norbornane ring, and <span class="Italics">S</span>-oxidation.  Lurasidone is metabolized into two active metabolites (ID-14283 and ID-14326) and two major non-active metabolites (ID-20219 and ID-20220).
</p>
<p>Total excretion of radioactivity in urine and feces combined was approximately 89%, with about 80% recovered in feces and 9% recovered in urine, after a single dose of [<span class="Sup">14</span>C]-labeled lurasidone.
</p>
<p>Following administration of 40 mg of LATUDA, the mean (%CV) apparent clearance was 3902 (18.0) mL/min.  
</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="LINK_bc15f8e6-29f3-427e-b13b-e6d60a68ef21"></a><a name="section-13"></a><p></p>
<h1>13. NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9a0d5c3a-4d28-40fe-beef-141e413ad2d6"></a><a name="section-13.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">Carcinogenesis:</span> Lifetime carcinogenicity studies were conducted in ICR mice and Sprague-Dawley rats. Lurasidone was administered orally at doses of 30, 100, 300, or 650 (the high dose was reduced from 1200 in males) mg/kg/day to ICR mice and 3, 12, or 36 (high dose reduced from 50) mg/kg/day to Sprague-Dawley rats.
</p>
<p>In the mouse study, there were increased incidences of malignant mammary gland tumors and pituitary gland <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in females at all doses; the lowest dose tested produced plasma levels (AUC) 2 times those in humans receiving the maximum recommended human dose (MRHD) of 80 mg/day.  No increases in tumors were seen in male mice up to the highest dose tested, which produced plasma levels (AUC) 15-25 times those in humans receiving the MRHD.
</p>
<p>In rats, an increased incidence of mammary gland carcinomas was seen in females at the two higher doses; the no-effect dose of 3 mg/kg produced plasma levels (AUC) 0.7 times those in humans receiving the MRHD.  No increases in tumors were seen in male rats up to highest dose tested, which produced plasma levels (AUC) 10 times those in humans receiving the MRHD.
</p>
<p>Proliferative and/or neoplastic changes in the mammary and pituitary glands of rodents have been observed following chronic administration of antipsychotic drugs and are considered to be prolactin mediated.  The relevance of this increased incidence of prolactin-mediated pituitary or mammary gland tumors in rodents in terms of human risk is unknown <span class="Italics">[see Warnings and Precautions (<a href="#LINK_451577ea-5ce4-4f08-89b0-91372b3ded84">5.6</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_95e8657c-1343-48b5-86b5-ee0d2b0117ad"></a><a name="section-13.2"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">Mutagenesis:</span> Lurasidone was not genotoxic in the Ames test, the <span class="Italics">in vitro</span> chromosomal aberration test in Chinese Hamster Lung (CHL) cells, or the <span class="Italics">in vivo</span> mouse bone marrow micronucleus test.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_47bf0bd9-ae50-4b83-9d83-658ff5374f74"></a><a name="section-13.3"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">Impairment of Fertility:</span> Lurasidone was administered orally to female rats at doses of 0.1, 1.5, 15, or 150 mg/kg/day for 15 consecutive days prior to mating, during the mating period, and through day 7 of gestation.  Estrus cycle irregularities were seen at 1.5 mg/kg and above; the no-effect dose of 0.1 mg/kg is approximately 0.01 times the maximum recommended human dose (MRHD) of 80 mg/day based on body surface area.  Fertility was reduced only at the highest dose and this was shown to be reversible after a 14 day drug-free period.  The no-effect dose for reduced fertility was 15 mg/kg, which is 1.8 times the MRHD based on body surface area.
</p>
<p>Fertility was not affected in male rats treated orally with lurasidone for 64 consecutive days prior to mating and during the mating period at doses up to 150 mg/kg/day (12 times the MRHD based on body surface area).
</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_1030ddb1-de8f-440c-9978-34c4f06773ea"></a><a name="section-14"></a><p></p>
<h1>14. CLINICAL STUDIES
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b76555a7-d36d-422d-8679-991a630ca45f"></a><a name="section-14.1"></a><p></p>
<h2>14.1. <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></h2>
<p class="First">The efficacy of LATUDA for the treatment of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> was established in four short-term (6-week), placebo-controlled studies in adult patients (mean age of 38.8 years, range 18-72) who met DSM-IV criteria for <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>. One study included an active-control arm (olanzapine) to assess assay sensitivity. </p>
<p>Several instruments were used for assessing psychiatric signs and symptoms in these studies: </p>
<ol class="Arabic">
<li>Positive and Negative Syndrome Scale (PANSS), is a multi-item inventory of general psychopathology used to evaluate the effects of drug treatment in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>. PANSS total scores may range from 30 to 210. </li>
<li>Brief Psychiatric Rating Scale derived (BPRSd), derived from the PANSS, is a multi-item inventory primarily focusing on positive symptoms of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, whereas the PANSS includes a wider range of positive, negative and other symptoms of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>. BPRSd scores may range from 18 to 126. </li>
<li>The Clinical Global Impression severity scale (CGI-S) is a validated clinician-rated scale that measures the subject's current illness state on a 1 to 7-point scale. </li>
</ol>
<p>The endpoint associated with each instrument is change from baseline in the total score to the end of <br>week 6. These changes are then compared to placebo changes for the drug and control groups. </p>
<p>The results of the studies follow: </p>
<ol class="Arabic">
<li>In a 6-week, placebo-controlled trial (N=145) involving two fixed doses of LATUDA (40 or 120 mg/day), both doses of LATUDA at Endpoint were superior to placebo on the BPRSd total score, and the CGI-S. </li>
<li>In a 6-week, placebo-controlled trial (N=180) involving a fixed dose of LATUDA (80 mg/day), LATUDA at Endpoint was superior to placebo on the BPRSd total score, and the CGI-S. </li>
<li>In a 6-week, placebo and active-controlled trial (N=473) involving two fixed doses of LATUDA (40 or 120 mg/day) and an active control (olanzapine), both LATUDA doses and the active control at Endpoint were superior to placebo on the PANSS total score, and the CGI-S. </li>
<li>In a 6-week, placebo-controlled trial (N=489) involving three fixed doses of LATUDA (40, 80 or 120 mg/day), only the 80 mg/day dose of LATUDA at Endpoint was superior to placebo on the PANSS total score, and the CGI-S. </li>
</ol>
<p>Thus, the efficacy of LATUDA at doses of 40, 80 and 120 mg/day was established in two studies for each dose. However, the 120 mg dose did not appear to add additional benefit over the 40 mg dose (TableÂ 10). </p>
<table>
<caption><span>TableÂ 10: Summary of Results for Primary Efficacy Endpoints </span></caption>
<col>
<col>
<col>
<col>
<col>
<col>
<tfoot>
<tr class="First"><td colspan="6" valign="top"><p class="First">* adjusted p-value &lt;0.05 (except for olanzapine) </p></td></tr>
<tr class="Last"><td colspan="6" valign="top"><p class="First"><span class="Sup">a</span> Least Squares Mean (Standard Error) </p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="center" valign="top">Â <span class="Bold">Study Number</span>
</td>
<td class="Botrule Toprule" align="center" valign="top">Â <span class="Bold">Primary Endpoint</span>
</td>
<td class="Botrule Toprule" align="center" colspan="5" valign="top">Â <span class="Bold">LS Mean (SE)</span><span class="Sup">a </span><span class="Bold">Difference from Placebo in Change from Baseline</span><br>
</td>
</tr>
<tr>
<td class="Botrule Toprule" align="center" valign="top">Â </td>
<td class="Botrule Toprule" align="center" valign="top">Â </td>
<td class="Botrule Toprule" align="center" valign="top">Â <span class="Bold">LATUDA</span><br><span class="Bold">40 mg/day</span>
</td>
<td class="Botrule Toprule" align="center" valign="top">Â <span class="Bold">LATUDA</span><br><span class="Bold">80 mg/day</span>
</td>
<td class="Botrule Toprule" align="center" valign="top">Â <span class="Bold">LATUDA</span><br><span class="Bold">120 mg/day</span>
</td>
<td class="Botrule Toprule" align="center" valign="top">Â <span class="Bold">Olanzapine</span><br><span class="Bold">15 mg/day</span>
</td>
</tr>
<tr>
<td align="center" valign="top">Â 1 </td>
<td align="center" valign="top">Â BPRSd </td>
<td align="center" valign="top">Â -5.6<span class="Sup">*</span><br>(2.1) </td>
<td align="center" valign="top">Â - </td>
<td align="center" valign="top">Â -6.7<span class="Sup">*</span><br>(2.2) </td>
<td align="center" valign="top">Â - </td>
</tr>
<tr>
<td align="center" valign="top">Â 2 </td>
<td align="center" valign="top">Â BPRSd </td>
<td align="center" valign="top">Â - </td>
<td align="center" valign="top">Â -4.7<span class="Sup">*</span><br>(1.8) </td>
<td align="center" valign="top">Â - </td>
<td align="center" valign="top">Â - </td>
</tr>
<tr>
<td align="center" valign="top">Â 3 </td>
<td align="center" valign="top">Â PANSS </td>
<td align="center" valign="top">Â -9.7<span class="Sup">* </span>(2.9) </td>
<td align="center" valign="top">Â - </td>
<td align="center" valign="top">Â -7.5<span class="Sup">* </span>(3.0) </td>
<td align="center" valign="top">Â -12.6<span class="Sup">* </span>(2.8) </td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="top">Â 4 </td>
<td class="Botrule" align="center" valign="top">Â PANSS </td>
<td class="Botrule" align="center" valign="top">Â -2.1<br>(2.5) </td>
<td class="Botrule" align="center" valign="top">Â -6.4<span class="Sup">* </span>(2.5) </td>
<td class="Botrule" align="center" valign="top">Â -3.5<br>(2.5) </td>
<td class="Botrule" align="center" valign="top">Â - </td>
</tr>
</tbody>
</table>
<p>Examination of population subgroups based on age (there were few patients over 65), gender and race did not reveal any clear evidence of differential responsiveness. </p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_3b15c58a-fa4c-4a42-b1e1-4256780d8f35"></a><a name="section-15"></a><p></p>
<h1>16. HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">LATUDA tablets are white to off-white, round (40 mg), or <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> green, oval (80 mg) and identified with strength specific one-sided debossing , â€œL40â€? (40 mg), or â€œL80â€? (80 mg). Tablets are supplied in the following strengths and package configurations (Table 11): </p>
<table>
<caption><span>TableÂ 11: Package Configuration for LATUDA Tablets </span></caption>
<col width="34.1%">
<col width="34.1%">
<col width="31.8%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Â <span class="Bold">Tablet Strength</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">Â <span class="Bold">Package Configuration</span>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">Â <span class="Bold">NDC Code</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center">Â 40 mg</td>
<td class="Botrule Rrule" valign="top">Â Drum of 1,517,754</td>
<td class="Botrule Rrule" valign="top">Â 51148-001-01 </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center">Â 80 mg</td>
<td class="Botrule Rrule" valign="top">Â Drum of 754,561</td>
<td class="Botrule Rrule" valign="top">Â 51148-002-01 </td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="LINK_5f98f4ed-676d-42ba-bd30-39acdacf59fa"></a><a name="section-15.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">Storage</span></p>
<p>Store LATUDA tablets at 25Â°C (77Â°F); excursions permitted to 15Â° - 30Â°C (59Â° - 86Â°F) <span class="Italics">[See USP Controlled Room Temperature]</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_77a881d1-f6b4-49b6-a044-5ac8467a7052"></a><a name="section-16"></a><p></p>
<h1>17. PATIENT COUNSELING INFORMATION
</h1>
<p class="First">Physicians are advised to discuss with patients for whom they prescribe LATUDA all relevant safety information including, but not limited to, the following:
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_cf2fb6b4-76b2-49b2-be91-5cfced0421fb"></a><a name="section-16.1"></a><p></p>
<h2>17.1 Increased Mortality in Elderly Patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>-Related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span>
</h2>
<p class="First">Patients and caregivers should be advised that elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related psychoses treated with atypical antipsychotic drugs are at increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> compared with placebo.  LATUDA is not approved for elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> [s<span class="Italics">ee <a href="#LINK_48c8dd45-b54e-425d-94ca-27545cd41a23">Boxed Warning</a>; Warnings and Precautions</span> (<span class="Italics"><a href="#LINK_f0eaab5a-ee6c-4115-8951-37cea2c2763b">5.1</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_34454319-2ce4-4def-9dc9-9b07daf7569d"></a><a name="section-16.2"></a><p></p>
<h2>17.2 <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span>
</h2>
<p class="First">Patients and caregivers should be counseled that a potentially fatal symptom complex sometimes referred to as NMS has been reported in association with administration of antipsychotic drugs.  Signs and symptoms of NMS include <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, altered mental status, and evidence of <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (<span class="product-label-link" type="condition" conceptid="4088122" conceptname="Heart irregular">irregular pulse</span> or blood pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, and cardiac dysrhythmia) <span class="Italics">[see Warnings and Precautions (</span><span class="Italics"><a href="#LINK_9d59ec04-ae9a-4f61-93d2-f8eddd5387d0">5.3</a></span><span class="Italics">)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ef1018b5-c927-422a-832c-a8c2d9662a65"></a><a name="section-16.3"></a><p></p>
<h2>17.3 <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus
</h2>
<p class="First">Patients should be aware of the symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> (high blood sugar) and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus. Patients who are diagnosed with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, those with risk factors for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, or those that develop these symptoms during treatment should have their blood glucose monitored at the beginning of and periodically during treatment [s<span class="Italics">ee Warnings and Precautions</span> (<span class="Italics"><a href="#LINK_91fdf397-0baa-4105-aa32-7d65c78cb7b0">5.5</a></span>)].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7e65bb39-a899-4de2-948d-8b4e1a7c627e"></a><a name="section-16.4"></a><p></p>
<h2>17.4 <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span>
</h2>
<p class="First">Patients should be advised of the risk of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, particularly at the time of initiating treatment, re-initiating treatment, or increasing the dose <span class="Italics">[see Warnings and Precautions (</span><span class="Italics"><a href="#LINK_2ce5b9e9-505b-44a7-89cc-114eb12eda61">5.8</a></span><span class="Italics">)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7599ba01-95af-4919-a7bc-82c22e4fdf21"></a><a name="section-16.5"></a><p></p>
<h2>17.5 <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>
</h2>
<p class="First">Patients with a pre-existing low WBC or a history of drug induced <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> should be advised that they should have their CBC monitored while taking LATUDA [s<span class="Italics">ee Warnings and Precautions</span> (<span class="Italics"><a href="#LINK_122095da-5dfb-4f21-90dd-ec35a78ecf1f">5.7</a></span>)].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_be175176-8a71-4c09-8f4f-7c8c14d3981b"></a><a name="section-16.6"></a><p></p>
<h2>17.6 Interference with Cognitive and Motor Performance
</h2>
<p class="First">Patients should be cautioned about performing activities requiring mental alertness, such as operating hazardous machinery or operating a motor vehicle, until they are reasonably certain that LATUDA therapy does not affect them adversely <span class="Italics">[see Warnings and Precautions (</span><span class="Italics"><a href="#LINK_39d6b752-fbbf-434f-bb41-3329ed9c9358">5.10</a></span><span class="Italics">)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c88101e9-0173-44ad-822d-0b5ed9e337e8"></a><a name="section-16.7"></a><p></p>
<h2>17.7 Pregnancy and Nursing
</h2>
<p class="First">Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during therapy with LATUDA <span class="Italics">[see Use in Specific Populations (<a href="#LINK_c20e55f7-c404-41eb-81a7-59d2a6be3975">8.1</a>)]. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_194cb528-6716-4eb1-9830-cf5e20bded58"></a><a name="section-16.8"></a><p></p>
<h2>17.8 Concomitant Medication and Alcohol
</h2>
<p class="First">Patients should be advised to inform their physicians if they are taking, or plan to take, any prescription or over-the-counter drugs, since there is a potential for interactions.  Patients should be advised to avoid alcohol while taking LATUDA <span class="Italics">[see Drug Interactions (<a href="#LINK_605c9ec5-aaa8-4e40-8c8b-acb62c67cd39">7</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_27d4a0a3-e721-4d3f-acf0-2d350b079548"></a><a name="section-16.9"></a><p></p>
<h2>17.9 Heat Exposure and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span>
</h2>
<p class="First">Patients should be advised regarding appropriate care in avoiding overheating and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> <span class="Italics">[see Warnings and Precautions (<a href="#LINK_e7fdffc2-a5ad-45a1-8ae1-e6001dfc3c18">5.11</a>)].</span></p>
<p>SUNOVION
</p>
<p>Manufactured for:<br>Sunovion Pharmaceuticals Inc.<br>Marlborough, MA 01752,
</p>
<p>For Customer Service, call 1-888-394-7377.<br>For Medical Information, call 1-800-739-0565.<br>To report suspected adverse reactions, call 1-877-737-7226.
</p>
<p>Revised: October 2010<br>901456R01
</p>
<p>LATUDA is a registered trademark of Dainippon Sumitomo Pharma Co. Ltd.  <br>Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Dainippon Sumitomo Pharma Co. Ltd.
</p>
<p>Â© 2010 Sunovion Pharmaceuticals Inc.
</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_31848b37-18af-4c10-b919-d79a8f82e3bc"></a><a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - 40 mg </span></p>
<p><span class="Bold">LURASIDONE Hydrochloride tablets 40 mgÂ <br>NDC 51148-001-01<br><br></span><span class="Bold"><span class="Underline">Caution<br></span>For Manufacture, Processing or Repacking. Rx Only<br>Store at 25ÂºC(77ÂºF). Excursions Permitted to 15-30ÂºC (59-86ÂºF)</span></p>
<p><span class="Bold">Bushu Pharmaceuticals Ltd.<br>Takeno, Kawagoe, Saitama, 350-0801, Japan<br><br><img alt="PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - 40 mg " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=88a244d1-eddb-499c-bee2-e1f49056e78f&amp;name=lurasidone-hydrochloride-2.jpg"><br></span><br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_5e55f098-e007-41c2-9025-af866b1ec7b1"></a><a name="section-18"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - 80 mg</span></p>
<p><span class="Bold">LURASIDONE Hydrochloride tablets 80 mgÂ <br>NDC 51148-002-01<br><br>Caution<br>For Manufacture, Processing or Repacking. Rx Only<br>Store at 25ÂºC(77ÂºF). Excursions Permitted to 15-30ÂºC (59-86ÂºF)</span></p>
<p><span class="Bold">Bushu Pharmaceuticals Ltd.<br>Takeno, Kawagoe, Saitama, 350-0801, Japan<br><br><img alt="PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - 80 mg " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=88a244d1-eddb-499c-bee2-e1f49056e78f&amp;name=lurasidone-hydrochloride-3.jpg"></span></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LATUDAÂ 		
					</strong><br><span class="contentTableReg">lurasidone hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:51148-001</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LURASIDONE HYDROCHLORIDE</strong> (LURASIDONE) </td>
<td class="formItem">LURASIDONE HYDROCHLORIDE</td>
<td class="formItem">40Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CARNAUBA WAX</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (ROUND) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">L;40</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:51148-001-01</td>
<td class="formItem">1517754  in 1 DRUM</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA200603</td>
<td class="formItem">10/28/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LATUDAÂ 		
					</strong><br><span class="contentTableReg">lurasidone hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:51148-002</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LURASIDONE HYDROCHLORIDE</strong> (LURASIDONE) </td>
<td class="formItem">LURASIDONE HYDROCHLORIDE</td>
<td class="formItem">80Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CARNAUBA WAX</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GREEN (green) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (OVAL) </td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">L;80</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:51148-002-01</td>
<td class="formItem">754561  in 1 DRUM</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA200603</td>
<td class="formItem">10/28/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Bushu Pharmaceutical, LTD.
							(693460169)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Bushu Pharmaceuticals, LTD.</td>
<td class="formItem"></td>
<td class="formItem">693460169</td>
<td class="formItem">ANALYSIS, LABEL, MANUFACTURE, PACK</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>c32a791b-3b0a-418d-a5e2-f63010a2d88e</div>
<div>Set id: 88a244d1-eddb-499c-bee2-e1f49056e78f</div>
<div>Version: 1</div>
<div>Effective Time: 20101118</div>
</div>
</div>Â <div class="DistributorName">Bushu Pharmaceutical, LTD.</div></p>
</body></html>
